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“To cease to think creatively is to cease to live.”
— Benjamin Franklin

FRoG: a fast robust analytical dose engine on GPU for p, 4He, 12C and 16O
particle therapy
Radiotherapy with protons and heavier ions landmarks a novel era in the field of high-
precision cancer therapy. To identify patients most benefiting from this technologically
demanding therapy, fast assessment of comparative treatment plans utilizing different ion
species is urgently needed. Moreover, to overcome uncertainties of actual in-vivo physical
dose distribution and biological effects elicited by different radiation qualities, development
of a reliable high-throughput algorithm is required. To this end, we engineered a unique
graphics processing unit (GPU) based software architecture allowing rapid and robust dose
calculation. Fast dose Recalculation on GPU (FRoG) currently operates with four par-
ticle beams, i.e., raster-scanning proton, helium, carbon and oxygen ions. Designed to
perform fast and accurate calculations for both physical and biophysical quantities, FRoG
operates an advanced analytical pencil beam algorithm using parallelized procedures on
a GPU. Clinicians and medical physicists can assess both dose and dose-averaged lin-
ear energy transfer (LET) distributions for proton therapy (and in turn effective dose by
applying variable RBE schemes) to further scrutinize plans for acceptance or potential
re-planning purposes within minutes. In addition, various biological model predictions are
readily accessible for heavy ion therapy, such as the local effect model (LEM) and micro-
dosimetric kinetic model (MKM). FRoG has been extensively benchmarked against gold
standard Monte Carlo simulations and experimental data. Evaluating against commer-
cial treatment planning systems demonstrates the strength of FRoG in better predicting
dose distributions in complex clinical settings. In preparation for the upcoming transla-
tion of novel ions, case-/disease-specific ion-beam selection and advanced multi-particle
treatment modalities at the Heidelberg Ion-beam Therapy Center (HIT), we quantified
the accuracy limits in particle therapy treatment planning under complex heterogeneous
conditions for the four ions (p, 4He, 12C, 16O) for various dose engines, both analytical al-
gorithms and Monte Carlo code. Devised in-house, FRoG landmarks the first GPU-based
treatment planning system (non-commercial) for raster-scanning 4He ion beams, with an
official treatment program set for early 2020. Since its inception, FRoG has been installed
and is currently in operation clinically at four centers across Europe: HIT (Heidelberg,
Germany), CNAO (Pavia, Italy) , Aarhus (Denmark) and the Normandy Proton Therapy
Center (Caen, France). Here, the development and validation of FRoG as well as clinical
investigations and advanced topics in particle therapy dose calculation are covered. The
thesis is presented in cumulative format and comprises four peer-reviewed publications.

FRoG: eine schnelle robuste analytische Dosis-Engine für die GPU mit p, 4He,
12C und 16O Partikeltherapie
Strahlentherapie mit Protonen und schweren geladenen Teilchen hat eine neue Ära der
Krebstherapie eingeleitet. Um Patienten, die von dieser technisch anspruchsvollen Me-
thode am meisten profitieren würden, zu identifizieren, ist ein schneller Vergleich von
Bestrahlungsplänen mit unterschiedlichen Teilchenarten unabdingbar. Aus diesem Grund
wurde ein neuartiges, Graphikkarten-basiertes Computerprogramm geschrieben, welches
schnelle und robuste Dosisberechnung ermöglicht. Fast dose Recalculation on GPU"(engl.
für ßchnelle Dosis-Nachberechnung mit Graphikkartenprozessoren"), FRoG, unterstützt
Dosisberechnungen für Protonen-, Heliumionen-, Kohlenstoffionen- und Sauerstoffionenbe-
strahlung. FRoG wurde mit einen hochentwickelten, analytischen Pencil-Beam-Algorithmus
entwickelt, der die Parallelität von Grafikkartenberechnung ausnutzt. Dies erlaubt schnelle
und präzise (bio-) physikalische Dosisberechnung. Mediziner und Medizinphysiker erlan-
gen mit FRoG Zugang zu Dosis-gewichtetem linearen Energie Übertrag von Protonen und
daraus folgend auch zu effektiver Strahlendosis durch Anwendung verschiedener Biophy-
sischer Modelle für RBE. Sie können damit innerhalb Minuten entscheiden, ob ein Be-
strahlungsplan akzeptabel ist oder neu geplant werden muss. Darüber hinaus sind auch
verschiedene biophysikalische Modelle für Teilchenbestrahlung mit schweren Ionen, wie
LEM oder MKM, integriert. FRoG wurde ausführlich gegen Monte Carlo Simulationen,
die als Maßstab in der Teilchentherapie gelten, und experimentelle Messungen verifiziert.
Der Vergleich zu einem klinisch verwendeten Bestrahlungsplanungssystem zeigte außerdem,
dass FRoG besonders in komplexen klinischen Szenarien Strahlendosis genauer vorhersagen
konnte. In Vorbereitung auf die bevorstehende Einführung von neuen Teilchen, Fall und
Krankheitsspezifische Bestrahlungsplanung oder komplexen Mehr-Ionen-Plänen für die Tu-
morbestrahlung für die Teilchenbestrahlung am Heidelberg Ionenstrahl-Therapiezentrum
(HIT) wurde die Genauigkeitsgrenze in der Bestrahlungsplanung unter komplexen und
heterogenen Bedingungen für die vier Teilchenarten analysiert. Dabei wurden sowohl ana-
lytische Programme, als auch Monte Carlo Simulationen verwendet. FRoG ist das erste
GPU basierte (nicht kommerzielle) Bestrahlungsplanungssystem für 4He Heliumionen im
Rasterscan-Verfahren, mit denen ab 2020 behandelt wird, und wurde vor Ort für das HIT
entwickelt. In diesem Zusammenhang wurden auch die biophysikalischen Aspekte von He-
liumionen mit in-vitro Clonogenic-Assays, Monte Carlo Simulationen mit existierenden
RBE Modellen untersucht, und FRoG für biologische Dosisberechnung mit Heliumionen
validiert. Seit seiner Entwicklung ist FRoG an vier Standorten innerhalb Europa installiert
worden: am HIT (Heidelberg, Germany), am CNAO (Pavia, Italy), in Aarhus (Dänemark)
und am Normandy Proton Therapy Center (Caen, France). Hier werden sowohl die Ent-
wicklung und Validierung von FRoG, als auch klinische Untersuchungen und erweiterte
Themen in der Dosisberechnung von Teilchenstrahlen vorangetrieben. Diese Thesis wird
im kumulativen Format vorgelegt und beinhaltet vier von unabhängigen Experten begut-
achtete Publikationen.
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1 Introduction
1.1 Motivation
Radiotherapy (RT) is a cornerstone in the treatment of cancer. Nearly two-thirds
of all cancer patients receive some form of radiotherapy. Most of these patients
undergo either photon- and/or electron-based therapies due to their longstanding
use, accessibility and cost (Baskar et al. 2012), including brachytherapy or external
beam radiotherapy (Daniel Bourland 2011). Particle therapy, on the other hand,
is on the rise, offering treatment options for patients with unresectable, inoperable
and radio-resistant tumors, as well as sensitive patients e.g. in pediatrics where
minimization of radiation dose to healthy tissues is critical.
The concept of particle therapy was first developed at Harvard University by a
group of scientists led by Robert Wilson in 1946 (Wilson 1946, Endo 2018) and sub-
sequently adopted years later by the Lawrence Berkeley Laboratory (LBL), where
years of experimentation to characterize both physical and biological properties of
various ion beams and the first proton therapy patient treatments in 1954 took place
(Lawrence et al. 1963, Lawrence et al. 1965, Lyman and Howard 1977). Techno-
logical advances in the last decade have made these cutting-edge modalities more
accessible to the general public. Through application of state-of-the-art delivery sys-
tems, such as three-dimensional intensity-controlled raster scanning, patients with
aggressive radio-resistant disease can be effectively treated. Currently, the lead-
ing modalities in hadrontherapy use protons and carbon ion beams (Durante et al.
2017).
Radiotherapy’s mechanism lay predominately in damaging deoxyribonucleic acid
(DNA) and fundamental structures of tumorous cells by the process of ionization,
inducing either direct or indirect damage (Fig. 1.1). Single strand break (SSB), dou-
ble strand break (DSB) production, or even more more complex clustered strand
breaks, can activate various cellular responses, leading to repair, disrepair or pro-
grammed cell-death (Hall et al. 1988, Goodhead 1994, Goodhead 2006). Cancer
is inherently an invasive and aggressive disease with high order of dysfunction, re-
sistance to treatment and fast proliferation. Fast proliferating tissues are most
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susceptible to radiation-induced death due to their inability to properly repair DNA
damage. This is a key factor in the efficacy of radiotherapy.
The first localization of tumor cells is referred to as the primary cancer and can
eventually progresses by invading (metastasize) other parts of the body. The tra-
ditional approach to treating cancer involves surgery, radiotherapy, chemotherapy
or a combination of these treatments (Durante and Loeﬄer 2010). Experimental
therapies such as immunotherapy and adjuvant treatments also show promise to
improve clinical outcome (Oiseth and Aziz 2017, Lee et al. 2018).
Figure 1.1 – Indirect versus direct radiation-induced DNA damage.
For all curative cancer treatments (as opposed to palliative), the main goal is eradi-
cation of malignant cells while sparing healthy tissues and critical organs. In radio-
therapy, this balance is crucial to assure tumor control and decrease risk of radiation
induced effects and secondary cancer in the normal tissue. Hence, target conformity
is a key clinical concept during treatment planning and delivery, aiming to increase
dose to the tumor while reducing dose to normal healthy tissues. So, the physical
quantity dose (D) for a particles (dN) traversing and infinitesimal cylinder of cross
sectional area dA and thickness dx is defined as
D ≡ energy
mass
=
−(dE/dx)× dx× dN
ρ× dA× dx (1.1)
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or more simply
D ≡ Φ S
ρ
(1.2)
In short, dose equals fluence (Φ), which is the time-integrated particle flux, times
mass stopping power (S), which is the retarding force acting on the charged particle
radiation (ρ) (Jennings 1994). Absorbed dose is expressed in the unit of the Gray
(Gy = J/kg).
Theoretically, particle beams have the greatest potential for normal tissue sparing
compared to conventional modalities like photons and electrons (linear attenuation),
since the characteristics of particle beam dose deposition provide more advantageous
physical distributions and biological effects (Schardt et al. 2010). Figure 1.2 depicts
relative dose deposition curves for various radiation qualities available at the Hei-
delberg University Clinic, for photon (γ) and particles (protons (1H), helium (4He )
ions, carbon (12C) ions and oxygen (16O) ions). The Bragg peak (BP) refers to the
entire depth dose distribution measured for a specific beam energy of particles and
is this characteristic curve in particle therapy. The integral depth dose for each BP
as a function of depth is commonly measured in a water tank for each treatment
room during commissioning. The depth of BP’s maximum can be manipulated as a
function of energy. To uniformly deliver a specified prescription dose in a target, a
superposition of those BP’s varying in energy, position and spot-size form the spread
out Bragg Peak (SOBP).
A trade-off then has to be considered to satisfy this balance between an effective
treatment and avoiding/decreasing complications and risk of secondary cancer in the
normal tissue. In order to achieve this goal, conventional radiotherapy techniques
using high energy photons evolved to provide a more conformal dose delivery to
the tumor, with technologies such as the multi-leaf collimator (MLC) (Boyer et al.
2001). The degree of conformity using collimation is limited, however, due to the
primary physical interaction mechanisms for photons with energy in the therapeutic
range (coherent scattering, incoherent scattering, etc.), yielding a significant lateral
penumbra. Additionally, due to linear attenuation, photon treatments often use
several beams with different angles/entry points to increase dose to deep-seated tu-
mors. Due to their more favorable physical properties, ion beams are seen as an
attractive alternative to photons. Currently, all treatment prescriptions for both
photon- and particle-based therapies are constructed from decades of clinical ex-
perience with photon treatments. Tumor control probability (TCP) and normal
tissue complication probability (NTCP) models help guide the clinician in assign-
ing success rates to specific treatment regimens while balancing risk of damaging
healthy tissues (Baumann and Petersen 2005). In practice, the dose-volume his-
togram (DVH) is a vital computational tool to evaluate and visually quantify the
quality of a treatment plan’s target (tumor) dose coverage and the degree of healthy
tissue sparing. of Quantitative Analyses of Normal Tissue Effects in the Clinic
(QUANTEC), for example, provides insight into the current clinical estimates for
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Figure 1.2 – Qualitative comparison of depth-dose profiles for different radiation qualities:
photons (γ), protons (1H), helium (4He ) ions, carbon (12C) ions and oxy-
gen (16O) ions. Generalized Bragg peak (black arrow) and spread out Bragg
peak (orange arrow) are plotted, demonstrating unique physical character-
istics when using particle beams as opposed to conventional photon based
radiation, where maximal dose deposition occurs at the entrance and di-
minishes as a function of depth. To reach prescription doses in deep-seated
tumors, photon treatments will use multiple beam angles to avoid delivering
high doses to normal tissues within the entrance channel, while particle treat-
ments may require only a single field and improve normal tissue sparing with
reduced dose and volume irradiated compared to photons. Particle therapy
modalities include passive scattering and active (raster) scanning. The latter
involves "painting" dose within a target through a superposition of beam-
spots with a particular size (w) and fluence (N) to create volume of delivered
dose, generated by cycling through energy slices (E) for BP depth positioning,
and altering lateral position of each spot (x,y) via steering magnets.
healthy tissue constraints and the predictive power of RT-related toxicity (Bentzen
et al. 2010).
1.2 Physics of charged particles
The basis of the physics of particle radiation with matter begins with the Bethe-
Bloch equation, first derived in 1933, to describe the energy loss as the mass stopping
power in an elementary material Z with atomic number A:
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−
〈
dE
dx
〉
= Kz2
Z
A
1
β2
[
1
2
ln
2mec
2β2γ2Tmax
I2
− β2 − δ(βγ)
2
]
(1.3)
where K and Tmax which represent constants and the maximum energy transfer in
single collision, respectively, are described as
K = 4piNAr
2
emec
2 = 0.307MeVg−1cm2
Tmax = 2meC
2β2γ2/
(
1 + 2γme/M + (me/M)
2)
with z and M represent the charge and mass of incident particle. Z, A and I indicate
the charge number, atomic mass and Mean excitation energy of medium. δ is a
density correction for the transverse extension of electric field, β = v/c, Avogadro’s
number Na = 6.022×1023, the rest energy of an electron mec2 ≡ 0.511 MeV and the
radius of an electron re = e2/4piε0meC2 = 2.8fm. I, for the purposes of this work,
can be used as an adjustable parameter of the theory during simulation.
The Bethe-Bloch equation is one fundamental description of physical phenomena
in particle physics with both non-relativistic and relativistic solutions. By reducing
terms and constants, one major take away is the energy loss dependence on mass A
and charge Z of target nucleus approximated as
−
〈
dE
dx
〉
∼ Z
A
(1.4)
which is also referred to at the stopping power (S). The mean projected (theoretical)
range of an accelerated particle can be described as
R (Einitial ) =
∫ Efratu
Eminul
(
1
ρ
dE
dx
)−1
dE =
∫ Emath
Etral
dE
S/ρ
(1.5)
in units of g/cm2.
Practically however, energy loss does not occur as a continuous process, but instead
as a finite number of individual interactions. Therefore, energy loss can be considered
a statistical phenomenon and consequently, leading to errors in predicted versus
measured range for a single particle known as range straggling (or energy straggling).
Practically, particle beam range is not measured for a single particle, but instead
for a specific beam-line in several bunches or spills (on the order of tens of millions
of particles) for improved statistics (Ondreka and Weinrich 2008). The net range
of the particle beam is often quantified by a particular distance at which the fall-
off dose reaches a certain percentage of the maximum BP, e.g. 80% (R80). As for
stopping power, there are two main components to the stopping power — nuclear
and electronic. Nuclear Stopping is more important for low energy heavy particles.
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The main component is the electronic stopping which refers to projectile ion slowing
down due to the inelastic collisions between bound electrons within the traversed
medium.
As previously stated, one can consider the energy loss of particle radiation as a
continuous process on a macroscopic scale. However, to most accurately model
physical (and biological) effects of radiation, understanding the spatial distribution
of energy loss and dosimetric characteristics of particle radiation on a microscopic
scale is essential. The degree (or frequency) of energy loss within the radiation track
structure is commonly referred to as the linear energy transfer (LET), defined as
the energy deposited per unit distance along the track (i.e. −dE/dx) in units of
keV per µm (Nikjoo et al.). Regarding its definition within the track structure,
LET commonly considers the entire “infratrack” (centralized narrow track region
approximately five interatomic distances radially) and a part of the “ultratrack”
(outer shell caused by secondary electron induced excitations and ionizations which
escape from the infratrack). For ion projectiles, the infratrack defines the region
in which electrons of the traversed medium are attracted towards the positively
charged particle. In terms of biology, an increased LET can produce more damage
with increased complexity, which influences a cellular system’s repair mechanisms,
either due to the frequency or severity of damage. Dose-averaged LET (LETd) values
of clinical significance range from ~1 keV µm-1 to ~12 keV µm-1 for protons, ~4 keV
µm-1 to ~50 keV µm-1 for helium ions, ~12 keV µm-1 to ~150 keV µm-1 for carbon
ions and ~14 keV µm-1 to ~180 keV µm-1 for oxygen ions. Biological repercussions
of radiation induced damage are briefly introduced in the following section.
1.3 Radiobiology of charged particles
For an equivalent local energy deposition (i.e. dose), particle beams are more ef-
fective than photons. To describe radiation induced death in a cell population, one
can describe the cell survival (S), traditionally described as a linear-quadratic (LQ)
with
S = exp (αD + βD2) (1.6)
where α and β represent the linear and quadratic coefficients, respectively, as a
function of physical dose (D). The ratio of the linear and quadratic coefficients,
(α/β)x), is often referred to as a description for the sensitivity of the cell line when
exposed to photon radiation (x). Since a lower dose of particle radiation is required
to produce the same biological effect when using photon radiation, we define the
relative biological effectiveness (RBE) where
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RBE[endpoint] =
Dx
Dz
(1.7)
where RBE represents the iso-effective dose ratio between a particle radiation (Dz)
and a reference radiation (Dx) and is modeled as a function of various endpoints.
RBE is known to vary with tissue type ((α/β)x), dose (Dz) and LET; however these
relations are complex and many recent efforts aim to devolve it’s multi-dimensional
dependencies (Fig. 1.3). In general, RBE increases with decreasing dose and α/β)x,
while RBE increases with increasing LET until a certain maximum where a satura-
tion effect occurs. LET is, however, a crude descriptor for the complex track damage
of particle radiation and has been demonstrated as a poor indicator for RBE (even
for protons) (Giovannini et al. 2016). In addition, the relationship of LET and RBE
is particle species dependent, i.e. RBE for 12 keV µm-1 protons does equate 12 keV
µm-1 carbon ions. Consideration of a mixed radiation field (i.e. the energy and
particle species spectra) is therefore required for appropriate modeling of RBE for
heavier ions.
Figure 1.3 – "Understanding RBE." RBE is a complex quantity with both known and
unknown endpoints. Traditionally, particle species, dose, tissue type and
LET are the main dependencies. The ongoing classification and modeling
of RBE within the field aims to unravel these main dependencies, as well as
incorporate characteristics of the cellular environment, genomic factors and
other patient-specific parameters.
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From a practical standpoint, the RBE is a useful quantity for translating fraction-
ation scheme, site-specific prescription doses, and dose constraints to critical struc-
tures from the photon world, since, in comparison to photons, substantially fewer
patients have been treated with particle beams. From here, biological (or effective)
dose is straightforward:
DRBE = RBE ×D (1.8)
To begin modeling the biological effectiveness of ion beams within the LQ framework,
we can determine a dependency of RBE on the photon and particle radiation LQ-
parameters. Considering that an absorbed dose D of particle radiation (D) and a
photon dose (Dx) are iso-effective if
αD + βD2 = αxDx + βxD
2
x (1.9)
Then, we define two ratios composed of linear and quadratic terms separately:
RBEα ≡ α
αph
(1.10)
Rβ ≡ β
βph
(1.11)
Next using equations 10 and 11, equation 9 can be rewritten as follows:
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to better highlight the dependence of RBE on photon parameters α/β)x and Dx,
as well as particle beam parameters RBEα and Rβ. If one performs derivations as
function of the particle radiation dose, RBE is defined as
RBE
((
α
β
)
ph
, D,RBEα,Rβ
)
=
− 1
2D
(
α
β
)
ph
+
1
D
√
1
4
(
α
β
)2
ph
+ RBEα
(
α
β
)
ph
D + RβD2
(1.13)
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There are several approaches to modeling RBE with different expressions for RBEα
and Rβ, however most rest on the LQ-framework from a biophysical or mechanis-
tic standpoint, as well as phenomenological (or data-driven) for the lighter ions
(p and 4He). In terms of clinical applications, centers in Europe and parts of
Asia (i.e. China) apply the local effect model version I (LEM-I), first developed
in 1997, while Japanese centers, which initially handled dose-response with a lin-
ear–quadratic model (Kanai et al. 1999), currently apply the Microdosimetric Ki-
netic model (MKM) (Hawkins 1998, Hawkins 2003, Inaniwa et al. 2010). These
models are both based on biophysical principles (considering various factors such
as reference radiation dose–response, track structure, initial DNA damage, target
sizes, etc.) yet have inherently different approaches to calculation.
For LEM, LQ-parameters (intrinsic αz and βz) and dose threshold (Dt) are the main
inputs (for each particle from Z =1 to Z = 6) via the PT RBE Generator software by
Siemens following previous reports, while for MKM, the saturation-corrected dose-
mean specific energy (z∗1D ) for is computed with a specific radius of the domain (Rd)
and the radius of the cell nucleus (Rn). Phenomenological approaches rely heavily on
the (in vitro) data available in the literature for development tuning. Recent works
collected and reviewed such models currently available for proton beams (Rorvik
et al. 2018. These models are discussed in more detail in Chapter 2, Publication
D.
1.4 The Heidelberg Ion-beam Therapy Center
(HIT) and the Biophysics in Particle Therapy
(BioPT) group
The Heidelberg Ion-beam Therapy Center (HIT) is a synchrotron-based clinical
facility (as opposed to cyclotron-based accelerators commonly used by major vendors
in proton therapy) with an active beam scanning (or raster-scanning) delivery system
similar to the prototype at previously developed in decades prior during the pilot
project GSI Helmholtz Centre for Heavy Ion Research (Darmstadt, Germany). The
ion beams originate from sources which produce positively charged ions (p, 4He, 12C
or 16O). A linear accelerator (commonly referred to as a Linac) accelerates the ions
to 10% the speed of light. Once the ions enter the synchrotron, they circulate several
million times and are subsequently accelerated to 75% the speed of light. The ion
beams are then led to the treatment rooms (2 × fixed-beam and 1 × heavy-ion
gantry) and the path is optimally directed via steering magnets which can induce
shift horizontal or vertical shifts (Haberer et al. 2004). Since its inception in 2009,
over 5000 patients have been treated with either protons or carbon ions (Fig. 1.4).
The synchrotron can accelerate 255 discrete energies for protons, helium ions and
carbon ions with a max range of 32 cm (205 discrete energies for oxygen ions with
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a max range of 23 cm). Energies for the proton and helium ion beams reach up
to 220 MeV/u and 430 MeV/u for carbon and oxygen ions. The current clinical
modalities at HIT include protons or carbon ions, with plans to start up the world’s
first raster-scanning helium ion-beam therapy program within the next year.
The HIT clinic uses the SyngoPT® commercial TPS (Siemens, Erlangen, Germany)
for treatment planning with protons and carbon ion beams. SyngoPT® was devel-
oped in collaboration with GSI and their in-house developed TPS, TRiP98 (Kramer
and Scholz 2000, Krämer 2009). SyngoPT® allows calculation of physical and bio-
logical dose distributions using the LEM-I for RBE predictions of carbon ion beams
(Scholz et al. 1997), while for protons, a constant RBE value of 1.1 is assumed the
clinically accepted standard worldwide (Paganetti et al. 2002). The treatment plan-
ning systems (TPS) uses an analytical approach to dose calculation (in the case of
SyngoPT®, a type of ray-casting called WEPL-to-POI). The TPS calls on a physi-
cal database (obtained either through experimental measurements or measurement-
validated Monte Carlo simulations during facility start-up/commissioning) describ-
ing the integral depth-dose and lateral dose profiles as a function of depth. Com-
missioning of a new clinical TPS (RayStation, RaySearch, Stockholm, Sweden) is
underway at HIT, capable of both MC simulation and analytical code calculations.
To fully exploit charged particle therapy (CPT) with the utmost precision, mod-
elling and predicting biophysical processes elicited from particle beam interactions
within the human body, must be performed on both macroscopic and microscopic
scales. To this end, a newly formed research group, "Biophysics in Particle Therapy
group (BioPT)", has been based at HIT and the Heidelberg University Hospital. As
opposed to traditional research groups, BioPT serves as a direct link between clinical
physicians and physicists to experimental techniques in radiotherapy. Additionally,
BioPT aims to introduce advanced computational methods for CPT into clinical en-
vironments, improve the accuracy of the clinical treatment planning systems (TPS)
used daily by clinicians, support the validation, commissioning and routine clini-
cal use of the TPS against dosimetric and in vitro biological measurements, and
develop both analytical and Monte Carlo simulation-based tools. A combination
of these efforts with clinical investigations using large patient cohorts aims to link
clinical outcome to physical, biological and clinical endpoints to utilize light and
heavy ion therapy in more patient-specific treatment agendas.
1.5 Dose calculation in particle therapy
Dose calculation plays a pivotal role in the particle therapy treatment chain. In
its earlier form, radiotherapy planning was conducted through a series of so-called
"hand calculations" for each delivered beam using tabulated reference dose curves.
While considering appropriate tuning and dosimetric correction factors (e.g. daily
fluctuations in temperature, pressure, etc.), necessary machine output factors known
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Figure 1.4 – The Heidelberg Ion-beam Therapy (HIT) facility (left), depicting the fixed-
beam and gantry treatment rooms which deliver clinical beams (protons and
carbon ions). A breakdown of clinical cases (right) is shown in the pie chart,
with a majority of treatment cases in head and neck anatomical sites. Other
represents treatments for liver, abdominal, extremities, pancreatic, etc.
as monitor units (MUs) or particle units (PUs) were estimated to reach prescription
dose levels at a particular depth. Before the age of computers, these methods were
understandably tedious and simplistic. Nowadays, dose computation with 3D mod-
eling of the patient is routine, capable of generating sophisticated treatment plans
e.g. intensity modulation via use of a multi-leaf collimator (mostly for photons) and
active scanning pencil beam delivery methods.
The first requirement of a clinical TPS is that, compared to gold standard measure-
ments and/or Monte Carlo simulations, its dose calculation engine must be accurate.
The advantages BP in particle therapy is both advantageous feature (due to its in-
herent targeting) and potential risk, since the range is highly sensitive to uncertainty
on the order of 2-3% (Paganetti 2012), especially in complex heterogeneous struc-
ture (like in a patient). Secondly, the TPS must be fast to meet the clinical needs
during patient-specific treatment planning and quality assurance (QA). Attaining
both accuracy and speed is a challenging feat but in spite of this, the two aspects
of dose calculation have become even more critical as the demand for the particle
therapy modalities increases and delivery techniques become more advanced (e.g.
adaptive radiation therapy (ART) with on-board imaging). The clinical TPS is a
powerful tool and is therefore be considered the workhorse in radiotherapy. The TPS
is traditionally composed of an analytical algorithm (a set of functions or routines
to approximate radiation physics) allowing for fast dose optimization, computation
and assessment within the clinical time-frame.
Prior to treatment, each patient will undergo a series of imaging procedures using
computed tomography (CT) systems and/or magnetic resonance imaging (MRI).
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CT images provide electron density information, represented in diagnostic images
as Hounsfield Units (HU), while MR images provide soft-tissue contrast. Both image
modalities are vital to modern-day radiotherapy treatment planning. CT scans pro-
vide a 3-dimensional model of the patient to determine how the radiation transport
will occur by correlating a particular image metric (conventionally HU) to stopping
power ratio relative to water (SPRw) in a scanner/protocol (scanner setting) spe-
cific look-up-table (LUT). This is particularly vital for particle therapy treatments,
in that anatomic density will alter the finite range of the particle beam. As for
MR images, physicians will use this enhanced soft-tissue visibility, not clearly dis-
tinguishable on CT images, to contour the tumor volume as well as healthy tissue
and organs-at-risk (where dose minimization takes place during treatment plan op-
timization). After patient-specific information and modeling are available in the
clinical TPS, patient treatment optimization is made possible.
Prior to facility start-up however, the clinical TPS will undergo a series of benchmark
tests and validations to ensure the complex treatment planning procedures meet
desired tolerances. In terms of dose prediction accuracy, Monte Carlo simulations are
considered the gold standard but are often time-consuming. Here, a brief description
of dose computation methods in particle therapy, Monte Carlo and analytical, will
be introduced.
1.5.1 Monte Carlo codes
Computer simulations are useful tools during research and development. Modern-
day Monte Carlo (MC) simulations, first theorized and applied during the Manhat-
tan project in 1944 in the development of nuclear weapons, enable the mathematical
representation of experimental conditions. In cases where experiments or measure-
ments cannot be practically carried out, Monte Carlo systems offer a solution by
incorporating physics models and information within a contained virtual environ-
ment, allowing research scientists to provide a "best-guess" (prediction) to nearly
unanswerable questions (or immeasurable experiments). The accuracy of these an-
swers depends on the proximity of the simulation (geometry and physics models) to
reality. For example, in the upcoming manned missions to Mars, how much radia-
tion will astronauts be exposed to on the Martian surface? What is the necessary
amount of shielding to reduce risk of radiation-induced effects or diseases? Likewise,
in regard to radiation oncology, what is the delivered dose to the patients? Unlike
a physics experiments, we cannot directly probe or measure dose deposition within
a patient during treatment to the degree that is desirable. Therefore, predictions,
either via Monte Carlo or other means, are the main reference during treatment
planning of verification.
Monte Carlo codes sample from stochastic distributions to simulate physics on a
step-by-step basis by iterating the physics of each particle; their transport is based
1.5 Dose calculation in particle therapy 13
on interaction probabilities (per unit distance) known as cross sections. In real-
ity, interactions are discrete processes which include nuclear interactions, secondary
particle production (including δ-electrons), and large angle Coulomb scattering.
In order to produce simulation resultants with an acceptable level of statistical
strength in a typical radiation treatment, a large number of particle histories must
be performed and therefore, are not only computationally intensive but also time-
consuming. It is therefore clinically preferable to use simplified physics calculation
codes on a daily basis.
In this work, Monte Carlo simulations are performed using FLUKA to verify a par-
ticular experiment or evaluate dose engine performance (Ferrari and others 2005,
Böhlen et al. 2014, Battistoni et al. 2016). FLUKA is a general purpose tool and
Monte Carlo code for calculations of particle transport and interactions with matter.
Written in FORTRAN77, FLUKA was first developed in the 1960’s (European Organi-
zation for Nuclear Research (CERN)) and is continually under-development today.
The internal simulation framework known as FICTION is based on prior efforts
which meticulously generated a simulation geometry/model of the HIT beam-line
(Parodi et al. 2012, Bauer et al. 2014, Tessonnier et al. 2016). FLUKA and FIC-
TION are particularly useful from both a clinical and research perspective, serving
as the "gold standard" reference (in combination with measurements, when avail-
able) and verifying treatment plans calculated with analytical dose algorithms, like
that of the standard clinical TPS.
1.5.2 Analytical algorithms
From a clinical standpoint, analytical dose calculation models are the most practical
method of estimating particle radiation transport in a particular medium. The pencil
beam (PB) model is the most common approach to approximate the geometric and
physical characteristics of particle beam dose-deposition (Hong et al. 1996). Figure
1.5 depicts a generalized case of a water phantom placed a distance from the particle
beam-line, with rays (black), points (black, presenting BP positions) and target
delineation (red).
Here, we describe the dose calculation of a voxel in a 3-dimensional (3D) geometry
as
d(x, y, z) =
numPBs∑
i=1
Ni × IDD(z, E0)×G(x, y) (1.14)
where for i number of indiviual PBs, each with a unique particle fluence (Ni), the
central term IDD is the integral depth-dose curve as a function of depth in water
(zeff ) of a particular initial beam energy E0, and the auxiliary term G describes
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Figure 1.5 – Generalized dose calculation scenario with a beam-line and particular (homo-
geneous) volume. The black rays and points represent an individual ray-trace
and corresponding BP position, respectively, with the target delineated in red.
the lateral evolution of the pencil beam, commonly modeled by a superposition of
Gaussian functions. For each ray trace as depicted in Figure 1.5, G(x, y) is computed
for each voxel within the dose grid (neglecting dose cut-off/thresholds, e.g. 3 ×σ for
the highest order term). Subsequently, for a single PB, equation 14 can be expanded
as
d(x, y, z) = N × IDD(z, E0)× [(1− w) ·G1 (r, σ1 (zeq, E)) + w ·G2 (r, σ2 (zeq, E))]
(1.15)
where G1 and G2 represent functions to describe a double Gaussian model, depen-
dent on r =
√
x2 + y2 and σi where i=1 and i=2, respectively, and the Gaussian
weight (1-w) and (w) are the normalization factors for G1 and G2, respectively.
Numerous works develop and implement models for lateral dose evolution of partic-
ular beams, such as double Gaussian (DG) (Parodi et al. 2013, Shen et al. 2016),
triple Gaussian (TG) (Inaniwa et al. 2009, Inaniwa et al. 2014) and non-Gaussian ap-
proaches (Embriaco 2015, Bellinzona et al. 2016, Embriaco et al. 2017). Considering
the generalized equation for a normal (Gaussian) distribution G = 1
σ
√
2pi
e−
1
2
((x−µ)/σ)2
and substituting into equation 15 yields the following:
d(x, y, z) = N × IDD(z, E0)×
[
1− w
2piσ21
·
∫
dye
(
−x2+γ2
2σ21
)
+
w
2piσ22
·
∫
dye
(
−x2+γ2
2σ22
)]
(1.16)
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Both the beam-spread in air from the nozzle (treatment head) to the surface en-
try and dose evolution within the medium can be modeled by Gaussian distribu-
tions. The initial beam spot-size is commonly characterized as a single Gaussian
(SG) at the isocenter with a certain energy-dependent full width at half maximum
(FWHM), where FWHM = 2
√
2 ln 2σ). Therefore, the contribution of beam spread
by the various component can be expressed as the quadratic sum of the individual
σ components
σtotal = σ
2
0 + σ
2
air + σ
2
medium (1.17)
where σ0 (initial spot size), σair (beam spread in air) and σmedium (lateral dose
evolution) can each be described as multi-Gaussian models. Recent works access the
gains of implementing a triple Gaussian (TG) beam model into research-based or
clinical dose engines (Inaniwa et al. 2014, Inaniwa et al. 2015, Embriaco et al. 2017).
Figure 1.6 demonstrates importance of implementing higher order Gaussian fitting
particle beams and the differing depth dose properties for the four ions available at
HIT.
Figure 1.6 – Lateral dose evolution for a single pencil beam within the Bragg peak (mid-
range energy proton beam). Monte Carlo against single Gaussian (SG) and
double Gaussian (DG) fits (left). Depth dose and lateral dose maps for SOBPs
(3x3x3 cm3) for four ions (right).
In summary, a ray-trace is performed for each ray, determining distance from the
source, and the water equivalent path length (WEPL) of each intercepted voxel.
Subsequently, corresponding IDD and G parameters are computed for each con-
tributing pencil beam. As opposed to Monte Carlo simulations, which can perform
dose-to-medium (Dm) calculation, by incorporating known material compositions
16 Chapter 1 Introduction
for each unique material, analytical algorithms rely on beam-data collected during
commissioning, usually characterized in water. Therefore, dose-to-water (Dw) is the
standard clinical endpoint.
Particle interactions in homogeneous settings (infinite planar slab geometry) are
well understood; however, limitations in analytical algorithms arise in scenarios with
complex geometries and heterogeneities (spatial variation in anatomic density e.g.
bone/tissue/air interfaces such as the skull-base or thorax region), which essentially
accounts for every dose computation performed in the clinic outside the routine QA
tests performed in homogeneous water phantoms and/or PMMA blocks. Therefore,
it is critical for analytical codes to consider the effects of anatomic heterogeneities
on the dose distribution.
Two main classes of heterogeneity handling have been proposed in previous reports:
(i) ray casting and (ii) pencil beam splitting. Ray casting operates by correcting
density heterogeneities with simple scaling of the water-equivalent depth (WED)
of each dose grid calculation point along the field direction which "deforms" the
pencil beam shape laterally. Pencil beam splitting offers an adaptable approach
(variable/adaptive splitting multiplicity) and have the potential for high accuracy,
but can be computationally intensive (Kanematsu et al. 2009, Russo et al. 2016).
The mathematical formalisms applied in the presented thesis are detailed the Ap-
pendix. Each method has own its benefits and trade-offs. For example, ray casting
methods are computationally fast and perform sufficiently well in handling superfi-
cial heterogeneities but may overestimate the effect of PB deformation (detailed in
Publication C ). PB splitting is adaptable and can yield a high degree of accuracy
but may have issues producing effect of inhomegeneities close to the targets.
Recent efforts in particle therapy dose engines have focused on speed by pushing
serial-based operations on the central processing unit (CPU) to parallelized compu-
tation on the graphic processing unit (GPU) (Jia et al. 2014). In terms of hardware,
the advantages of a GPU over a CPU, is the large number of processing units. De-
spite GPU clock speed being relatively low compared to the CPU, the combined
processing power can outperform CPU for most executions (i.e. when all GPU
executions, which occur in parallel threads known as warps, process in the same
execution path). For example, if-else functions may cause a warp diverge and put
other threads in an idled state. This feature makes vector and matrix operations
(e.g. analytical dose calculation algorithms) the ideal operation for GPU. In con-
trast, maintaining high speeds for GPU-based Monte Carlo codes is challenging due
to the stochastic nature of modeling particle interactions, which would cause fre-
quent divergent independent threads. Pseudo-code of CPU- versus GPU-based dose
computation is shown below:
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;
where a iterative loop of x×y×z CPU-based processes can be replaced with a single
execution on the GPU. From here, it becomes apparent that the iterative execution
using an analytical PB dose calculation, with many kernels can be independently
handled, are ideal for the GPU.
Physical dose is not the only parameter of interest for computation in particle ther-
apy. Scoring additional metrics such as LETd using analytical algorithms can occur
on the fly:
LETd =
∑N
i=1 Di × LETi∑N
i=1Di
(1.18)
Similarly, computation of RBE-weighted dose requires dose-averaged scoring for
parameters with:
αmix =
∑
i di · αi · wi∑
i di · wi√
βmix =
∑
i di ·
√
βi · wi∑
i di · wi
(1.19)
z∗1Dmix(x) =
∑
i di(x) · z∗1Di(x) · wi∑
i di(x) · wi
(1.20)
such as α and β correspond to the linear and quadatric terms of the LQ-model,
while z∗1Dmix(x) represents the saturation-corrected dose-mean specific energy.
1.6 Aim of the thesis: development, validation and
application of FRoG
Currently in the clinic, there is an absent pipeline for efficient testing and imple-
mentation of innovative models, advanced computation and new-age treatments in
particle therapy. As previously stated, the clinical standard worldwide for effec-
tive dose prescription and treatment planning in proton therapy assumes a constant
RBE of 1.1, a conservation estimate despite evidence of variable RBE and high-
LET effect along the BP (Paganetti et al. 2002, Chaudhary et al. 2014, Peeler et al.
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2016). For carbon ions, facilities like HIT implemented LEM-I, which is still in clin-
ical use today (Combs et al. 2010) despite more update-to-date versions presenting
substantially different predictions (Gillmann et al. 2019). Moreover, both leading
modalities in particle therapy have yet to integrate LET-related effects into clinical
decision-making. The clinical TPS is often a "black box" program which does not
afford flexibility for in-house development. Recent works developed or expanded
secondary systems in-house (e.g. TRiP, Astroid, matRad and FoCa) and bench-
marked against their model center’s clinical treatment planning system (TPS) for
educational purposes or clinical support (Wieser et al. 2017, Sánchez-Parcerisa et al.
2014, Krämer et al. 2016, Kooy et al. 2010). However, the accuracy of such pencil-
beam (PB) algorithms may be less than satisfactory in challenging patient cases
with considerable heterogeneity. Moreover, most platforms, like the clinical TPS,
have limited flexibility and speed (CPU-based) when advanced metrics are desired
(e.g. LETd and DRBE) for studying large patient cohorts. Monte Carlo simulations
can however support clinical and research investigations in radiotherapy, but most
codes cannot meet the needs of the clinic and require extensive physics and pro-
gramming expertise. Therefore, recent efforts have focused on increasing speed of
accurate yet time intensive codes for proton therapy by pushing to the GPU (Jia
et al. 2012a, Jia et al. 2014).
In this work, we present the Fast Robust dose calculation on GPU (FRoG) plat-
form, initially developed in-house at HIT in 2018 as a GPU-based auxiliary analyt-
ical dose engine to support research and clinical activity at HIT for the four ions
available: protons (1H), helium (4He ) ions, carbon (12C) ions and oxygen (16O)
ions (Mein et al. 2018, Choi et al. 2018). As depicted in Figure 1.7, FRoG is a
multi-purpose sandbox environment written in python and C++ to perform rapid
and accurate computations using a PB model (Hong et al. 1996) with triple Gaus-
sian lateral evolution parameterization (Inaniwa et al. 2009, Inaniwa et al. 2014)
and GPU-optimized Siddon raytracing (Siddon 1985) for physical dose, LETd, RBE
and effective dose. The FRoG project began as a collaboration project between HIT
and the National Centre for Oncological Hadrontherapy (CNAO, Pavia, Italy) but
has expanded to additional centers in Europe. FRoG aims to support both large
research institutions and smaller clinics which lack the resources and man-power to
establish a substantial research support team locally within the clinic.
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Figure 1.7 – FRoG diagram detailing base features and functionality.
The publications collected for the cumulative thesis detail the development, valida-
tion and application of FRoG for various research and clinical scenarios in particle
therapy. The main aims of the thesis, addressed in the four published works, are as
follows:
i. development of a fast GPU-based analytical dose engine for various modalities
in particle therapy (FRoG).
ii. validation of various particle therapy dose engines (both Monte Carlo and an-
alytical) in both homogeneous (simple) and heterogeneous (clinical-like) set-
tings.
iii. Applications of FRoG to support clinical and research activity at two distinct
hadrontherapy facilities (HIT and CNAO).
Lastly, future works and challenges regarding the development and application of
fast robust dose engines in ion therapy are explored in the Discussion section.

2 Publications
This thesis is presented in ‘cumulative’ format in accordance with the regulations of
the Department of Physics and Astronomy of Heidelberg University. It comprises
four articles published in internationally recognized peer-reviewed journals. The
individual manuscripts are referred to within this thesis with alphabetical order-
ing (A, B, C, and D). The dissertation is part of the FRoG collaboration formed
between HIT and CNAO in 2017. All work was performed in close collaboration
with Kyungdon Choi (CNAO, Pavia, Italy), Benedikt Kopp (DKFZ, Heidelberg,
Germany) and PD. Dr. Andrea Mairani (HIT, Heidelberg, Germany). The main
focus of the thesis is Heidelberg-based development, methodologies, experimental
validation, and applications. The secondary focus of the thesis involved external
collaborations and applications (mainly in Pavia, Italy and Caen, France). Specific
author contributions to each article are stated in the respective following sections. A
timeline is displayed in Figure 2.1 labeled with corresponding publications (A-D).
Figure 2.1 – Timeline of projects and related publications. Note: (*) indicates ongoing
projects which are presented in the Discussion section.
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3 Discussion
In this chapter, the key concepts, findings and achievements for dose calculation
in particle therapy are discussed and are contextualized within the current state of
the relevant literature. From the four published works which comprise the cumula-
tive thesis, the major aims achieved are as follows. A GPU-accelerated analytical
dose engine for p, 4He, 12C and 16O ion therapy (FRoG) was developed. Its dose
calculation performance was evaluated experimentally for both homogeneous and
heterogeneous settings as well as in relation to other existing Monte Carlo and an-
alytical systems at two distinct hadrontherapy facilities (HIT and CNAO). Finally,
the biophysical phenomena of a novel treatment modality using 4He ion beams are
investigated to integrate relevant models (both physical and biological) and to estab-
lish a framework for research and clinical support using FRoG. Additionally, future
and ongoing efforts in the development and application of fast robust dose engines
in ion therapy are explored in this chapter.
FRoG does not only provide an auxiliary platform for physical dose computation,
but also clinical metrics which are currently unavailable in the standard commer-
cial TPS such as LETd and RBE-weighted dose with innovative models (biophys-
ical/mechanistic and phenomenological). As proof of principle, Figure 3.1 depicts
biological dose computation for three particle therapy plans optimized with pro-
tons, helium ions and carbon ion beams. The proton plan was initially optimized
and calculated assuming RBE of 1.1 as performed in the clinic, and subsequently, a
forward calculation was performed using a phenomenological (data-drive) variable
RBE model Mairani et al. 2017b. The second plan (rightward) considers the differ-
ing biological perspective between Europe and Japan for model variable RBE with
carbon ions, by performing forward calculations of a chondrosarcoma patient plan
(previously treated at HIT, optimized with LEM-I) with MKM. These three case
studies each provide a unique perspective on the value of systems like FRoG which
readily allow testing of different models and metrics. That is, LETd and variable
RBE schemes are currently absent in the clinical decision making process for pro-
ton therapy and the AAPM TG-256 report suggests restructuring of the current
simplistic workflows for proton therapy. For the heavier ions, RBE model selection
should not be taken lightly since the clinical model will influence routine procedure
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and clinical outcome. The following sections will discuss FRoG’s performance as an
auxiliary dose engine in relation to other systems (both clinical and research based)
as well as gold standard measurements. It will also evaluate clinical potential for
systems to introduce advanced metrics and models (i.e. LET and variable RBE
for proton therapy) and explore the ongoing and potential studies such as clinical
outcome investigations and novel treatment delivery and verification technique de-
velopment using FRoG. Finally, applications beyond Heidelberg and future visions
for FRoG are considered.
Figure 3.1 – Comparison of effective dose prediction schemes for clinical particle beams.
Dose maps for a skull base chordoma patient (left) treated with protons ("pa-
tient A" from Publication A) and carbon ions ("patient D" from Publication
A) at HIT. For the proton case, the clinically assumed constant RBE = 1.1
and a variable RBE model (Mairani et al. 2017a) are applied. For carbon
ions, the NIRS- and HIT-based approaches (MKM and LEM-I, respectively)
are applied.
3.1 Performance as an auxiliary dose engine
Publication A presents the development and initial validation of FRoG against
FLUKA Monte Carlo simulations (the same Monte Carlo code used for FRoG base
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data generation i.e. energy dependent integral depth dose profiles and lateral dose
evolution) in both homogeneous and heterogeneous conditions (water phantom and
patient cases) for the four ions available at HIT. Validation of SOBP plans in water
demonstrated excellent agreement with FLUKAMonte Carlo within ~1% for protons
and ~2% for the heavier ions. The initial validation demonstrated the accuracy im-
provements with using higher-order lateral dose evolution parameterization (i.e. DG
vs. TG), particularly for the helium, carbon and oxygen ions. As for FRoG’s perfor-
mance with patient calculations, its accuracy stems from dual pencil beam (DPB)
model and sub-pencil beam superposition as described in the Appendix section of
the thesis. First detailed in Publication A, the DPM model is a unique approach
to the PB algorithm to separately handle primary particles interacting in the beam
applications and monitoring system (BAMS), which for the lighter particle beams
(protons and helium ions) induces large angle scattering and, in turn, a substantial
low-dose envelope. Consequently, the DPB model yields improved accuracy against
to Monte Carlo predictions when compared to conventional PB algorithms in het-
erogeneous structures but at the cost of increased run-times. The DPB model is,
however, specific to the HIT beam-line, and therefore, the times provided in table 1
of Publication A are higher than one would anticipate from a GPU-based analytical
code, with an average ~170 seconds per patient for the four ions. It should be noted
that the computation times account for physical dose, as well as LETd and several
RBE-weighted doses. Therefore, in the context of FRoG’s performance for other
centers, the average forward calculation of a patient case would take approximately
one minute, maintaining the same degree of PB subdivision. Moreover, as stated in
Publication A, dose kernel run-times per PB were in line with RayStation.
The initial development and validation of FRoG at HIT was accompanied by Pub-
lication B, which presents FRoG predictions at CNAO for physical dose, LETd and
effective dose as well as a validation of physical dose in various homogeneous set-
tings (SOBPs with varying field size and depth) for the clinical beams (protons and
carbon ions). In short, a dosimetric study of SOBP plans irradiated in a water
tank presented the following results: for proton beams, FRoG and SyngoPT® were
in agreement with ion chamber measurements within 0.7% an 1.0%, respectively.
For cases with the range shifter in-place, agreement was within 1.1% for FRoG and
1.4% for SyngoPT®. Additionally, a dosimetric study was performed for twenty-
five patient-specific QA fields irradiated in the water tank. Differences between
calculated and measured dose over the all fields were 1.96(±0.79)% for FRoG and
2.71(±1.25)% for SyngoPT®. Similar results were recorded for carbon ions. Fi-
nally, Publication B introduced LETd and RBE-weighted dose computations (using
both Japanese- and European-based approaches) for protons and carbon ions, re-
spectively, which demonstrated excellent agreement with Monte Carlo simulation.
Following the developmental and validation works, Publication C details a unique
dosimetric study at HIT with a challenging half-head anthropomorphic phantom
set-up for p, 4He, 12C and 16O ion beams. FRoG was validated with both 1D and
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2D ionization chamber measurement devices, with its performance tested against
full Monte Carlo simulation and a commercial TPS (SyngoPT®) for particle ther-
apy. The dosimetric measurements acquired during the study (especially with the
OCTAVIUS® system) were particularly valuable since they represent the first mea-
surements taken in anthropomorphic settings for 4He, 12C and 16O ion beam therapy.
Acquiring useful measurements in the distal-end/fall-off are challenging considering
range uncertainty in particle therapy. Additional tests are recommended in the near
future to verify range prediction and dose within the fall-off region for anthropomor-
phic phantom set-ups. Considering the upcoming clinical trials with helium ion at
HIT, FRoG shows promise as a viable analytical engine for helium ions, validated
against Monte Carlo and in vitro measurements for helium ion beam therapy (Mein
et al.), making way for next-generation modeling and dose computation. These
topics are discussed further in the sections that follow.
Performance of in-house systems (MCTP and FRoG) as well as the current clinical
TPS at HIT (SyngoPT® by Siemens, Erlangen, Germany) in heterogeneous condi-
tions is of particular importance since its a test which is more representative to the
clinical condition (patient anatomy) than homogeneous settings with a water phan-
tom and rectangular parallel-piped SOBPs. Simple tests are of course vital for initial
benchmarks, but by performing rigorous tests in this manner, systematic errors or
trends may become more apparent which are not routinely visible during quality
assurance (QA) procedures. For example, the SyngoPT® forward computation of
the proton SOBP behind the anthropomorphic has a distinct visual appearance and
visibly differs from the other computation methods (full Monte Carlo and analyt-
ical pencil beam splitting codes). We conclude in this work that the MCTP and
FRoG performed well in challenging conditions, as demonstrated by superior agree-
ment with measurements (generally within ~2% to ~3%) for the four ions, while
SyngoPT® presented clinically relevant discrepancies for the proton field. As elab-
orated in Publication A, FRoG compensates for the particular beam-line by (i) TG
parameterization of the lateral dose evolution and (ii) separately modeling primary
particles which interact in the BAMS from the pristine primary beam with the DPB
model.
Another intriguing experiment involved the in-house double-wedge phantom, which
tests dose calculation performance in anatomically complex scenario (Fig. 3.2). In
this test, plan optimization was performed using SyngoPT® and therefore the dose
map and profiles are homogeneous within the target of the SyngoPT® calculation.
Similar to the half-head anthropomorphic phantom investigations in Publication C,
MCTP and FRoG produced comparable distribution but with hot-spots generated
at the distal-end and variations observed up to ~15% in the target when compared
against SyngoPT®.
The Siemens system was first developed in mid-2000’s and based on a ray-casting
method called WEPL-to-POI. Depending on the approach to implementation and
the modeled beam-line, dose distribution prediction using WEPL-to-POI in complex
3.1 Performance as an auxiliary dose engine 89
geometries and for oblique beam angles, may present clinically relevant differences
compared to gold standard Monte Carlo simulations and measurements. End-of-
range measurements are especially challenging due to various factors like HU-WEPL
conversions using convectional CT methods used in the clinic. Moreover, Siemens is
no longer supporting development for SyngoPT®. For these reasons, installation and
validation of more update-to-date systems like RayStation® (RaySearch, Stockholm,
Sweden) are underway at HIT for treatment planning with protons and carbon ions.
Ongoing works will expand on the measurements from Publication B and Publication
C by including a more modern clinical TPS.
Figure 3.2 – Dose calculation performance testing (FLUKA vs. SyngoPT® vs. FRoG)
with the double-wedge phantom. Dose maps (top) and line profiles (bot-
tom), depth-wise and lateral, are provided. With the plan optimized using
SyngoPT®, SyngoPT® predicts a relatively homogeneous dose distribution
within the target. However, this results is no poor agreement demonstrate
FLUKA and FRoG, which predict hot-spots at the distal end, up to approx-
imately 15%. WEPL-to-POI may have performance issues for oblique beam
angles and geometric planes.
In the field of radiotherapy, there is a rising interest in secondary dose engines for
clinical QA purposes. IBA and research scientists from SciMoCaTM teamed up in
2018 to bring an auxiliary Monte Carlo verification tool to photon and electron
therapies (Ion Beam Applications S.A. 2018b). Related works in the literature
develop and evaluate the role of machine learning to perform so-called "virtual QA"
and its potential impact on clinical dose computation and workflows in the photon
world (Valdes et al. 2016, Valdes et al. 2017). However, extensions to particle therapy
dose engines have yet to be made commercially available. Such systems could greatly
streamline the tedious and redundant QA procedures. The role of secondary dose
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engines like SciMoCaTM and FRoG are expected to become more commonplace in
clinical environments.
Other GPU-based analytical engines (Da Silva et al. 2015, Fujimoto et al. 2011)
have been developed for proton therapy, most notably a recent ray-casting algorithm
capable of dose calculation and optimisation within 10 seconds (Matter et al. 2019).
As for fast Monte Carlo, several GPU-based codes have been published to support
clinical and research activity at their respective facility (Kohno et al. 2011, Yepes
et al. 2010, Jia et al. 2012a, Wan Chan Tseung et al. 2016, Schiavi et al. 2017, Li et al.
2017, Maneval et al. 2019). Apart from goCMC (Qin et al. 2017, Qin et al. 2018) which
performs GPU-based Monte Carlo prediction for carbon ions, existing platforms
are specific to proton beams, preserving the accuracy of the Monte Carlo while
substantially reducing computation times. Several works propose and investigate
the value of patient-specific QA using treatment delivery log files recorded after each
fraction (Zhu et al. 2015, Scandurra et al. 2016, Chung 2017, Johnson et al. 2019).
There is currently no streamlined protocol in particle therapy clinics to access and
perform quick computations using these patient-specific log files; however, secondary
systems like FRoG have demonstrated their capacity to handle log files and, through
rapid GPU-accelerated dose calculation, to access the impact of daily fluctuations
in treatment delivery parameters and uncertainties, e.g. fluence, spot position and
foci (Mein et al. 2018).
Several publications speculate the clinical impact of auxiliary systems, the future
role of variable RBE dose calculation in proton therapy and follow up with an
extension of the code to partnering centers, such as FRED at the Krakow proton beam
therapy centre (Garbacz et al. 2019) and FDC at the Shanghai Proton and Heavy
Ion Center (Wang et al. 2018). Similarly, FRoG was initially developed through
the HIT/CNAO collaboration and has been recently installed at Danish Centre for
Particle Therapy (DCPT) at Aarhus University Hospital (Skejby, Denmark) and the
Normandy Proton Therapy Center at François Baclesse Centre (Caen, France) to
support clinical and research activity (Fig. 3.3). Adaptation and intial validations
at the Normandy facility will be discussed in following sections.
3.2 Environment for advanced metrics and
models: LET and RBE
To this day, there is no commercial TPS which provides LETd prediction in the
clinic. In the case of protons, the standard clinical TPS provides a single biological
perspective (constant RBE = 1.1). The past decade has seen a myriad of works pub-
lish in vitro (Paganetti et al. 2002, Chaudhary et al. 2014, Paganetti 2012), in vivo
(Saager et al. 2018, Sørensen et al. 2011) or in man, providing evidence of observed
LETd effects (Peeler et al. 2016, Carabe et al. 2013). Other works evaluated the
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Figure 3.3 – FRoG Partnership map — besides the Heidelberg Ion-beam Therapy Center
(HIT), FRoG is supporting clinical and research activities the National Cen-
tre for Oncological Hadrontherapy (CNAO, Pavia, Italy), the Danish Center
for Particle Therapy (DCPT, Aarhus, Denmark) and the Normandy Proton
Therapy Center (Caen, France). FRoG is functional for both synchrotron-
and cyclotron-based facilities including Siemens, Varian ProBeam® and IBA
ProteusOne® beam-lines.
impact of a variable RBE in proton therapy clinical trials using different fractiona-
tion schemes (Dasu and Toma-Dasu 2013, Marshall et al. 2016), concluding that the
current clinical assumption most likely overestimates the therapeutic ratio in proton
therapy for liver cancer (Chen et al. 2018). These works should prompt swift action
by clinical environments to incorporate LET optimization into treatment planning,
or at the very least treatment selection based on favorable LET estimations (i.e.
reduced high LET in OARs or sensitive normal tissues) (Unkelbach et al. 2016, Un-
kelbach and Paganetti 2018). LET-based optimization techniques have been shown
to substantially reduce dose-response uncertainty (McMahon et al. 2018).
Notably, the effect of improper RBE assignment is not simply a tumor control issue
but manifests in the risk for normal tissue toxicity (Lühr et al. 2018, Jones et al.
2018). For instance, clinicians implement safety margins beyond the clinical target
volume (CTV) which comprises the disease bed; however, the effective range and
penumbra, especially at the distal end, may be expanded due to the increased effec-
tive dose in high-LET regions which potentially jeopardizes efforts to reduce toxicity
(Carabe et al. 2012, Giovannini et al. 2016). Recent reviews outline clinical imple-
mentation of variable RBE prediction as a move towards more personalised treat-
ment, especially considering inter-tumoral genomic heterogeneity, including DNA
damage response, is increasingly appreciated as a major contributor to variation
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treatment response (Willers et al. 2018). Despite these extensive works, consider-
able variability in both RBE measurement (in vitro and in vivo) and prediction
remains. Furthermore, many studies vaguely report physics and dosimetry parame-
ters used during radio-biological studies, which ultimately stunts reproducibility of
much needed data for proton RBE (Draeger et al. 2019).
In response to these immediate clinical issues, several phenomenological-based RBE
models for proton therapy have been published in the last decade, each with a
unique approach and tuned to an existing in vitro dataset (Wilkens and Oelfke
2004, McNamara et al. 2015, Wedenberg et al. 2013, Mairani et al. 2017b, Carabe-
Fernandez et al. 2007, Chen and Ahmad 2012, Unkelbach et al. 2016, Frese et al.
2011). These models are well summarized in a recent review (Rorvik et al. 2018) and
analyzed with respect to the clinical dose, LET and reference radiation fractionation
sensitivity range. With respect to in vivo dose-reponse, other works either measure
(Saager et al. 2018) or model RBE for clinically relevant endpoints (Lühr et al.
2017).
From a practical standpoint, the first step requires driving such metrics to the clinical
spotlight with fast, user-friendly dose engines such as FRoG. From here, LETd and
RBE models should be evaluated as a link to clinical outcome in patients. Novel
works propose and implement a mixed RBEmodel (MultiRBE) approach in matRad,
where uniform constant and variable RBE are applied in the target contours and
normal tissues, respectively (Sánchez-Parcerisa et al. 2019). The Multi-RBE is one
approach to incorporate variable RBE models in the clinic without severely altering
the current method of planning tumor coverage. Other works present a Monte
Carlo based framework to model radiation response for assessment of clinical RBE
variability in proton therapy (Eulitz et al. 2019).
Similarly, FRoG provides an intuitive platform for computing these advanced metrics
for four ions (p, 4He, 12C and 16O). Choi et al. demonstrated that FRoG predictions
for LETd values were in good agreement with Monte Carlo (within 0.3 keV µm-1 in
both the target and OARs). For carbon ions, both MKM- and LEM-based DRBE
calculations were implemented and validated against Monte Carlo to support dose
conversion between facilities using different biological perspectives.
As previously stated, FRoG is used during clinical operation at the Danish Center
for Particle Therapy (DCPT, Aarhus, Denmark), with other facility partnerships
planned or pending (Fig. 3.3). Upcoming works will provide a detailed account of
the adaptation, commissioning, and application of a fast (GPU-based) independent
dose calculation system for Varian and IBA-based proton therapy centers. As for re-
lated GPU-based projects, future efforts will develop and investigate next-generation
models with patient-specific clinically-accessible parameters such as measurable cell
or tumor micro-environment characteristics (Oesten et al. 2019, Arnold et al. 2018,
Chiblak et al. 2019).
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FRoG is ideal for fast assessment of comparative treatment plans of different ion
species, both prospectively and retrospectively with a large treatment diversity (e.g.
particle species, beam angles, number of beams), using robustness analysis and
large patient cohorts. To overcome uncertainties of actual in-vivo physical dose
distribution and biological effects elicited by different radiation qualities, a flexible
dose engine like FRoG can serve as a sand-box environment for testing innovative
models prior to clinical integration. This is particularly vital for upcoming clinical
trials (e.g. pancreatic) and introducing novel modalities to the clinic like raster-
scanning helium ion beams.
3.3 Investigating RBE for helium ions
An imminent internal application of FRoG is to support research and clinical activity
during the start-up of the raster-scanning helium ion beam therapy program at HIT
by 2020. As discussed in Publication D, helium ions exhibit favorable physical and
biophysical characteristics i.e. intermediate qualities between protons and carbon
ion fields, such as a reduced lateral scattering/penumbra and enhanced biological
effects compared to protons, with a reduced fragmentation tail compared to carbon
ions (Tessonnier et al. 2017c). Revisiting in vitro dose-response for helium ion beams
through the investigation of a cell line with a clinically relevant (α/βx) was a main
achievement of this work. Clonogenic cell survival assays were preformed following
the in-house protocol (Dokic et al. 2016) to test three RBE models for helium ions,
incorporated into a detailed FLUKA Monte Carlo simulation for the 96-well plate:
DDM (Mairani et al. 2016a), LEM-IV (Grün et al. 2012) and MKM (Inaniwa et al.
2010, Mairani et al. 2017b). Finally, RBE model performance was tested in silico for
patient cases and used to verify GPU-accelerated effective dose computation. FRoG
landmarks the first GPU-based dose engine for helium ions.
Since the shut-down of many clinical trials using helium ions at LBL decades prior
(apart from ocular melanoma which continued for several years after (Castro et al.
1997)), helium ion beams remain clinically unexploited. In short, the results of
the clinical trials were as follows: helium ions were advantageous when irradiat-
ing smaller tumors, traditionally treated with photon/electron-based treatments,
situated near radio-sensitive tissues (e.g. chondrosarcoma, melanoma, etc.). Con-
versely, large tumors did not respond well to helium ion radiation and due the
lack of substantial evidence of improved local control and survival using helium-
ion therapy, most trials were closed followed by pilot trials using heavier ions such
as neon (20Ne) ions, e.g. for pancreas carcinomas (Saunders et al. 2006, Linstadt
et al. 1988). Due to the relatively simplistic treatments compared to modern-day
planning and delivery methods (which assumed a constant RBE of 1.3 and used
passive-scattering techniques), one could speculate that, given the knowledge and
capabilities of the time-period, the clinical trials could not fully exploit the clinical
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potential of helium ions, leading to a relatively poor outcome compared to heavier
ions. One interpretation of these trial results relates to target volume dependency
of clinical outcome, since, for particle treatments, a tumor will experience hetero-
geneous, spatially-variant LET across the treatment volume. Depending on tumor
shape/volume and selected field configuration for delivery, regions of the tumor may
experience substantially different LETd and in turn, volume/RBE dependent effects.
For example, covering large target volumes requires many overlapping energy slices
and, compared to smaller targets, involves greater overlapping of entrance channel
dose with relatively low LET parts (< 10 keV) for helium ion beams.
Despite the lack-luster conclusions from the LBL clinical trials, a revival of interest
in helium ion beam therapy is taking place, with several publications added to the
literature and key-note talks presented at various international conferences in the
recent years (Ströbele et al. 2012, Fuchs et al. 2012, Fuchs et al. 2015, Mairani et al.
2016a, Mairani et al. 2016b, Krämer et al. 2016, Knäusl et al. 2016, Tessonnier et al.
2017c, Tessonnier et al. 2018). It is therefore valuable to revisit the basic features
of helium ion beams, not only in the context of the improved treatment delivery
techniques e.g. active scanning, but also in relation to the complex biological effects
and modeling variable RBE for treatment planning. An important question to ask
is the following: with nearly two decades of light and heavy ion treatments, what
have we learned from a constant RBE for protons and variable RBE for carbon ion
beams to best implement a novel modality such as helium ion beam therapy?
Recent works (including a doctoral thesis) performed extensive dosimetric charac-
terizations of helium ion beams (Tessonnier et al. 2017b, Tessonnier 2017). Several
SOBPs in water (ranging in field size and depth) were simulated and measured in
homogeneous settings (Tessonnier et al. 2017a). For improved modeling of helium
ion beams, particularly for higher energies where integral depth dose deviations near
the BP were detected on the order of ~6% (Tessonnier et al. 2017c), recently ac-
quired cross-section measurements were incorporated into the FLUKA Monte Carlo
simulation code (Horst et al. 2019) and validation is currently underway. Publication
C took further steps to evaluate the current status of simulating helium ion beams
with Monte Carlo methods and PB analytical algorithms in heterogeneous settings.
Through dosimetric investigations, this work constitutes the first measurements for
helium ion beams using anthropomorphic phantom set-ups. In such cases, we found
that uncertainty in physical dose prediction for helium ion beam is on the order of
~3%.
Publication D, on the other hand, determined biophysical uncertainties of roughly 5%
to 10% depending on the end-point, RBE model, investigated tissue type. The work
presented in Publication D is a continuation of previous work by first outlining the
short- and long-term goals for understanding RBE for helium ion beams, depicted
in Figure 3.5. Currently, there exists two clinical approaches to modeling variable
RBE for particle beam: LEM is applied at centers in Europe and China, while
MKM is applied in Japanese-base facilities. A modified MKM was recently made
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available to best reproduce in vitro cell survival data in clinically-relevant scenarios
for proton and 4He ion beams (Mairani et al. 2017b). A recently developed "data-
driven" phenomenological model for helium ion beams provides RBE estimates by
collecting and parameterizing the available in vitro data from the literature (Mairani
et al. 2016a, Mairani et al. 2016b). Additionally, a mechanism-inspired model called
the Repair-Misrepair-Fixation (RMF) model is implemeted for research purposes
(Kamp et al. 2014, Kamp et al. 2014, Kamp et al. 2014).
Prior the first patient treatment with helium ions, an RBE model must be selected,
integrated into the clinical TPS and extensively validated. This first requires an
evaluation of RBE models in their current state and their ability to predict radiation-
induced cell death, e.g. for in vitro experimentation. Figure 3.4.a depicts RBE
model variation for different LET levels and tissue radio-sensitivity factors (α/βx)
as a function of physical dose for four available RBE model for helium ions (LEM,
MKM, RMF, DDM). Additionally, in vitro data collected for the development of
the data-driven RBE model (DDM) for helium ions is presented in figure 3.4.b. In
terms of RBE uncertainty, low (α/βx) signifies a highly radio-resistant tissue that
is of particular interest due to the lack of data and substantial variability between
RBE models.
In Publication D, the Renca cell line was chosen to examine in vitro dose-response
for helium ion beams. We set out to verify the significant RBE enhancement ob-
served in the models for dose levels < 4 Gy, a clinically relevant range bearing in
mind the typical fractionation size for proton beams of ~2 Gy (RBE) (pathology and
treatment scheme dependent). One aspect of RBE modelling for helium worth dis-
cussing is the computation and handling of the β (quadratic) component of the LQ
model. For large Z particles, the β component is often negligible within the typical
fractionated dose range and in most conditions. For lower Z particles, however, Rβ
may exhibit LET-dependent trends more complex than currently understood. It is
therefore important to understand Rβ for both the primary beam of light ions and
mixed field radiation of heavy ion beams (e.g. modeling effective dose nuclear inter-
actions and fragmentation by-products). Close examination of the Rβ component
of the DDM model (Mairani et al. 2016a, Mairani et al. 2016b) reveals that for LET
of ~4 keV µm-1, Rβ converges to ~0.6, while for ~15 keV µm-1, Rβ approaches ~1.
Rβ parameterization was obtained by a convenient parameterization which fits the
running averages of the experimental data, neglecting any (α/β)x dependencies due
to the large uncertainties effecting the β term. Recent works develop a phenomeno-
logical model for proton beams from in vitro data following a similar approach to Rβ
handling by assuming a negligible (α/β)x dependency (Mairani et al. 2017b, McNa-
mara et al. 2015). Here, parameter fittings are merged to a relatively small amount
of data using a running average and thus, this work can shed light on RBE model
performance in regions where data is sparse and predictions exhibit large uncertain-
ties. Moreover, existing experimental data is especially scarce for low (α/β)x values
(< 3 Gy) (Mairani et al. 2016b), where the largest RBE values are expected and
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Figure 3.4 – a) RBE model variation for LEM (green), MKM (blue) and DDM (red) as a
function of physical dose for different LET levels and tissue radio-sensitivity
factors (α/βx). b) Data collected from in vitro clonogenic assay experiments
(αHe/βph), organized within three distinct cell line groups: low, moderate and
high radio-resistance (from top to bottom). The green arrows draw attention
to a region where no data is available within a clinically relevant LET range
(between 0 and <50 keV µ m-1. This figure was adapted from Mein et al.
and Mairani et al..
the highest variations among the models occur. Further data for low (α/β)x tissues
and for clinically-relevant dose levels, especially in standard fractionation regimes
(DRBE < ~3 Gy (RBE)), is essential for benchmarking the predictive power of
these RBE models. These relatively large uncertainties in Rβ fitting for lower LET
values (<10 keV µm-1) could be a main source of the disagreement of the models
with experimental data, which suggests that further in vitro study and tweaking of
the models would yield improved RBE predictions with the DDM. The biophysical
models would require refinement of their corresponding parameters (Mairani et al.
2017a). However, 5% to 10% predictive power for RBE in the target region is ex-
pected and acceptable considering the uncertainty of the reference photon sensitivity
measurement.
The results in Publication D may imply that systematic uncertainties in the predic-
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tion of RBE for helium ions for clinical scenarios are not primarily dominated by
the choice of the RBE model. But they may more notably be determined by the
choice of the in vitro dataset used for tuning the RBE model parameters and the
approach and methodology used for tuning itself. Similar conclusions might hold
also for RBE models for higher Z ion species. Nonetheless, MKM and DDM pre-
sented similar predictions across the various endpoints (i.e. dose and LETd) while
LEM-IV consistently underestimates dose-response for the lower LET conditions.
Additional systematic RBE uncertainties arise from differences between in vivo and
in vitro data. However, due to its scarcity, in vivo and clinical data are hardly used
to tune RBE models, but rather for validation of commonly established RBE models
(Saager et al. 2015), exception being the neutron-equivalent scaling point used for
carbon ions (59,60). Previous works also propose application of clinical data for
RBE model tuning in addition to in vitro and in vivo measurements (Cometto et al.
2014).
Publication D is by no means a complete evaluation of RBE prediction for helium
ions. Ongoing works will continue to investigate performance with additional cell
lines with a wide range of (α/β)x values as conducted more extensively for proton
beams (Chaudhary et al. 2014, Matsumoto et al. 2014, Howard et al. 2017, Guan
et al. 2015, Beyreuther et al. 2019). In addition, little is understood about the
sensitivity of the RBE models to input uncertainties for helium ions (e.g. absolute
values of αx and βx). Recent works have perform sensitivity studies using biophysical
models for carbon ions such as LEM and MKM (Böhlen et al. 2012, Grün et al.
2017, Kamp et al. 2017 Dahle et al. 2018). Aside from comprehensive evaluation of
biological effects and modeling for helium ion beams, ongoing efforts will present a
full validation of FRoG against dosimetric measurements, Monte Carlo simulation
and biological investigations to produce physical dose, LETd and RBE-weighted
dose for both clinical and experimental modalities in particle therapy.
3.3 Developing novel treatment and imaging
techniques for the clinic
The translation of innovative systems for treatment delivery and monitoring can
be drawn-out in series of initial testing and integration steps. Despite dedicated
research teams for routine clinical support, useful innovation in medicine may never
reach common practice without a transparent port to clinicians. With this in mind,
FRoG’s sandbox environment contains physics models necessary for dose prediction
and can foster development and testing of new techniques in particle therapy for
treatment delivery, monitoring and evaluation. As detailed in Section 3.2, the HIT
administration and clinical directors have set a start date for clinical trials using he-
lium ion beams. With no commercial treatment planning system currently available
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on the market, there is an immediate need for systems capable of generating treat-
ment fields, both physical and biological. In the case of commissioning and simple
testing, SOBP plan generation in homogeneous targets is a basic but essential fea-
ture, with systems like TRiP98 (Krämer et al. 2016), Hyperion (Fuchs et al. 2012,
Fuchs et al. 2015) and FRoG (Mein et al. 2018). Since FRoG is maintained in-house,
incorporates the latest physics models for helium ion beams (Horst et al. 2019) us-
ing the the FLUKA development version (as well as beam-line specific adaptations)
and is the sole GPU-accelerated helium dose engine, FRoG is currently the main
support tool for research and clinical investigations for helium ion beams. Initial
validations works of FRoG against Monte Carlo and measurements were performed
for both physical and biological dose computation (Mein et al. 2018, Mein et al.
2019a). These works were an ideal starting point however they only test a limited
set of conditions both physical (in terms of field size, dose level, geometry, etc.) and
biological (Renca, a/b ~ 2 Gy). For the purpose of developing a first generation of
treatment planning systems for helium ion beam therapy, further validation works
for FRoG version 1 (2018) are ongoing. Regarding RBE and effective dose computa-
tion for helium ion beams, there is no consensus as to which model is most suitable
for clinical application. Publication D samples a subset of clinical conditions (i.e.
tissue type, field attributes, RBE models) and future works should consider a more
long-term view for RBE study and model implementation as depicted in Figure 3.5.
Understanding RBE for helium ions remains a key issue in proper clinical use and
few recent works present initial estimates (Dokic et al. 2016). Despite the scarcity
of data, especially for pristine beams within the clinically relevant LET range, the
recently introduced data-driven RBE model (Mairani et al. 2016a, Mairani et al.
2016b) in conjunction with mechanistic models (i.e. LEM and MKM) can provide a
first prediction for initial studies. The accuracy of these models is dependent on the
reliability of the in vitro data used for tuning, and further efforts in understanding
RBE for helium ions is recommended, especially when considering recent review-
ers which shed light on issues of experimental reproducibility with radio-biological
studies (Draeger et al. 2019).
Since the initial release of FRoG, related efforts in the BioPT group have focused
on expanding FRoG functionality and dose engine integration into a fully equipped
system, known as the PRECISE TPS (PaRticle thErapy using single and Combined
Ion optimization StratEgies). At the moment, clinical assignment of particle beams
is purely circumstantial and can be dictated by the clinician’s preference, e.g. based
on prior indication or anecdotal evidence of clinical outcome from prior or ongo-
ing clinical trials. The PRECISE TPS aims to overcome these shortcomings by
providing a system which, for each patient, will generate a set of particle therapy
treatments based on a limited number of clinical inputs, for various particle species,
using both single and combined modalities. Little is understood about the clinical
advantages of combining ions and works within the BioPT group are currently un-
derway in this subject matter. Böhlen et al. first proposed reducing uncertainty
in effective dose prediction for carbon ion therapy by optimizing constant RBE
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Figure 3.5 – Long-term workflow of helium RBE study and clinical integration of RBE
models (biophysical and phenomenological). In vitro study and in silico com-
parisons (using Monte Carlo and analytical methods) for both monoenergetic
beams and clinically relevant conditions are underway. After analysis of the
predictive power of the RBE model (both intra- and inter-model variability),
preparation of clinical routines is possible, beginning with the validation of a
clinical TPS, capable of effective dose calculation for helium with the various
biological perspectives. With the anticipated clinical boot-up of the helium
ion beam therapy program at HIT, clinical studies (i.e. dose escalation) and
research-based in vivo investigations can lead to RBE model refinement for
improved clinical outcome. Clinical practice using RBE models for heavy
ions is location dependent i.e. MKM at Japanese centers and LEM mostly
at European centers (Italy and Germany).
treatments using multiple ions. Such an approach to optimization can theoretically
reduce potential gradients in biological dose prediction, considering uncertainties
in treatment planning, such as tissue radio-sensitivity assignment and the applied
biological model (Kopp et al. 2019). Similarly, concurrent works ongoing at NIRS
present a novel modality called IMPACT (Intensity Modulated comPosite pArtiCle
Therapy) (Inaniwa et al. 2017), which aims to expand therapeutic window via op-
timization of physical dose and LET. Research efforts at GSI focus on overcoming
hypoxia-related resistance via so-called "kill-painting" by combining low and high Z
to boost LET mid-target in parallel-opposed beam treatments (commonly used for
treatment of prostate cancer) (Tinganelli et al. 2015, Sokol et al. 2019).
In regard to treatment monitoring, innovative systems for particle beams such as
prompt gamma spectroscopy (Dal Bello et al. 2018, Dal Bello et al. 2019) and ion-
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beam radiography (Gehrke et al. 2017, Gehrke et al. 2018b, Gehrke et al. 2018a)
have been demonstrated as promising treatment verification techniques for particle
therapy and potentially reduce treatment delivery uncertainties by properly locat-
ing the BP in vivo (Parodi and Polf 2018). Such systems could benefit by inte-
grating with FRoG serving as a bridge between research and clinical environments.
Moreover, concurrent works in BioPT in the form of master’s theses will establish
and evaluate spectral-based stopping power prediction (as opposed to conventional
HU-SPR conversion with single energy CT systems) for improved particle range
estimation used during treatment planning (Mei et al. 2018, Landry et al. 2019).
Similar works investigate clinical viability of advanced dual-energy CT (DECT) sys-
tems to mitigate range uncertainties (Bär et al. 2017) and implement into clinical
practice (Wohlfahrt et al. 2017). Future aims with FRoG will support and propel
such imaging and treatment verification techniques into the clinic.
3.4 Application of FRoG beyond Heidelberg:
IBA-based facility
Apart from the initial development, validation and application at the base institu-
tions HIT and CNAO, FRoG can also be used during research and clinical routines
at a proton therapy center (PTC), currently the most common form of particle
therapy facility (PTCOG 2019). The modern-day PTC administers high-precision
cancer treatment using commercial treatment planning and delivery systems to pre-
dict patient dose, optimize coverage to deep-seated solid tumors, and minimize risk
of adverse effects in nearby healthy tissues. Joining a list of over 50 facilities in-
vested in IBA solutions (Ion Beam Applications SA, Louvain-la-Neuve, Belgium),
the Normandy PTC (CYCLHAD) at the Centre François Baclesse (CFB) opened
its doors to patients in August 2018, providing proton therapy treatments with the
IBA single-room Proteus®ONE using the RayStation® TPS (RaySearch, Stock-
holm, Sweden) (Ion Beam Applications S.A. 2018a). Such cyclotron-based delivery
systems operate using continuous selection (as opposed to discrete energies with a
synchrotron) and beam characteristics differ between offered treatment room models
as well as vendors using similar equipment. Additionally, treatment planning system
(TPS) features and specifications can vary in the context of available output, calcu-
lation mode (analytical or condensed history Monte Carlo), run-time and accuracy;
however, all commercial systems remain in a pre-compiled format throughout clin-
ical use, preventing the development, testing and integration of innovative physical
and biophysical models in particle therapy.
Considering these factors, clinical integration and validation of auxiliary systems,
which provide both secondary independent dose prediction during routine QA, as
well as advanced physical/biophysical parameters such as LET and RBE-weighted
dose, is recommended. Regarding RBE for proton beams, a constant value of 1.1 is
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accepted and applied as the clinical standard worldwide, as defined by ICRU, de-
spite evidence of variable RBE for protons. For the moment, there is no streamlined
solution to extend biophysical dose computation to the particle therapy clinic (e.g.
next-generation beam models, LETd and variable models) for protons. This is a
current setback in the field, especially for smaller clinics which lack the resources
and man-power to establish a research support team for the clinic. The AAPM Task
Group Report (TG) 256 advises proton therapy centers implement dose-weighted
LET into clinical decision-making at the very least to avoid unwarranted biological
effects in surrounding critical organs (Paganetti et al. 2019). Contrary to conven-
tional photon radiotherapy with nearly half a century of experience, there is no
widely accepted practice for verification of clinical performance using independent
dose calculation software. In a sense, the enhanced tumour-targeting features of par-
ticle therapy beams (inverted depth dose at end-or-range) make delivery susceptible
to uncertainty and therefore, robustness remains a key issue in treatment planning to
mitigate range uncertainty and biological effects neglected in the clinic. That being
said, one must note the importance of supporting the clinical TPS with advanced
secondary systems, e.g. analytical or Monte Carlo codes developed and maintained
in-house which offer gold-standard accuracy but require substantial physics and pro-
gramming expertise for time- and hardware-intensive computation. Recently, sev-
eral works by large research institutions present facility-specific dose engines, most
of which involve task parallelization on a GPU for enhanced speed and superior
accuracy compared to conventional systems.
Recently, the FRoG system was installed and commissioned at CYCLHAD to pro-
vide various treatment perspectives to clinicians, physicists and dosimetrists. This
mainly involved adapting dose computation procedures to a cyclotron-based facility
(continuous energy selection). Figure 3.6 presents results from the ongoing valida-
tion work of FRoG at the Normandy Proton Therapy Center, depicting FRoG dose
prediction against the clinical TPS (RayStation® Monte Carlo, RS-MC) and ion
chamber measurements. A representative patient case is additionally displayed in
Figure 3.7, demonstrating FRoG’s excellent agreement with a commercial Monte
Carlo dose engine. Additionally, LETd and effective dose calculated using a vari-
able RBE model (phenomenological) are presented (Mairani et al. 2017b). Recent
reviews assemble and analyze fourteen phenomenological RBE models for proton
therapy available in the literature, indicating roughly ~10% uncertainty increas-
ing (for clinical fields) towards the SOBP-end (Rorvik et al. 2018). It is therefore
paramount to better understand the behavior of these models and which are most
applicable for certain anatomical sites and treatment types (e.g. hyper- versus hypo-
fractionation, dose level, field-size, etc.).
Nonetheless, with FRoG as an auxiliary system for advanced dose computation and
verification in conjunction with the clinical TPS (RS-MC), physicians and physicists
may predict a more reliable “delivered biological dose” to the patient (compared
to current clinical standards), especially in challenging clinical cases, as well as
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incorporate LETd into treatment planning and clinical decision-making.
Figure 3.6 – Example FRoG base-data integral depth-dose and depth-LETd profiles (left)
and representative validation test with mid-range depth SOBP profiles
(FRoG and RS-MC) against ion chamber measurements (mea.).
At the moment, there is no clear workflow for how to best integrate new metrics
like LETd and variable RBE models into the clinics. Considering the uncertainties
in current RBE prediction, choosing a single existing model for clinical implemen-
tation may be a bit premature. At the moment, a more practical strategy may
involve LET-weighting alongside the conventional RBE of 1.1, e.g. LETd-based op-
timization techniques implemented into the clinical TPS at Massachusetts General
Hospital (MGH, Boston, Massachusetts, USA). Other major research-based facilities
as well as small satellite clinics operate using a clinical TPS without modifications
or secondary support systems beyond the status-quo in treatment planning. In the
meantime, systems like FRoG are compatible with beam-lines of the major pro-
ton therapy vendors (e.g. IBA and Varian) and can provide a training ground for
physicians and physicists to begin familiarizing with advanced biophysical endpoints.
Here, we offer a case-example for how auxiliary dose engines with LETd and variable
RBE functionality could influence clinical decision-making.
3.5 Future visions for FRoG
The GPU-accelerated aspects of FRoG are saliently attractive features for numerous
applications with large data-sets which require lengthy analysis and computation
times. Currently in particle therapy, there is a demand for investigations into clinical
efficacy and evidence-based practice with particle therapy. Interest is expanding for
both photon-based studies as well as inter-particle comparisons.
Interpretation of clinical outcome between facilities may be hindered, especially be-
tween the European and Japanese definition of RBE for carbon ions. Recent reports
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Figure 3.7 – Despite evidence of variable RBE for protons, there is no streamlined solution
to access innovative biophysical dose computation. Following recommenda-
tions of the AAPM’s TG-256, the FRoG platform provides a GPU-accelerated
analytical dose engine, capable of LETd and effective dose computation within
minutes, within good agreement of with dosimetric measurements and dose
calculated by RayStation Monte Carlo (RS-MC). Dose maps for RS-MC and
FRoG are provided (left) for a chordoma patient plan previously treated
in Caen, France. Resultant DVH for the PTV and brainstem are provided
(middle), along with LETd and DRBE maps (right).
investigate optic nerve constraints for carbon ions and aim to improve the European
RBE-weighted dose (DLEM) constraints by analyzing toxicity in relation to NIRS
RBE-weighted dose (DMKM) (Dale et al. 2019). This is of particular importance
since carbon ion prescription doses and constraints have mostly been defined and
validated within the Japanese biological perspective (Fossati et al. 2012, Fossati
et al. 2016, Molinelli et al. 2016). The clinical TPS, for the safety of the patient,
have the flexibility to readily change or compute effective dose with various RBE
models, and therefore, workarounds using educational or open-source third-party
software are useful for understanding clinic outcome (Wieser et al. 2017).
Other examples include FRoG based investigations such as late effect assessment in
particle therapy (LEAPt) which are currently underway. Figure 3.8 presents a po-
tential workflow in the LEAPt for analyzing a sub-set of prostate patient treatments,
such as the IPI trials (Habl et al. 2016) where 92 patients were treated with either
protons or carbon ions. Other recent works assess TCP (Uhl et al. 2014) and NTCP
with clinical endpoints for other pathology such as chordoma. FRoG-based investi-
gations will examine clinical outcome against LETd and variable RBE schemes (i.e.
beyond RBE 1.1 for protons and LEM-I effective dose for carbon ions).
In regards to program architecture, there are several projects in the works. In Figure
3.9, FRoG GUI version 2018 (v1.0) is displayed. It’s basic user-friendly layout
for both clinicians and research scientists yields flexibility and therefore, scripting
104 Chapter 3 Discussion
features are inherently possible with its open-source architecture written in python
and C++ for data-handling and rapid computations, respectively.
At the moment, FRoG functionality is limited to forward calculations; however,
broadening FRoG’s set of features is currently underway and will be operative within
the GUI through sub-commands called Lily Pads for both preset and customized
subprograms. To name a few, these processes include porting conventionally CPU-
based computations to the GPU such as 3D gamma tests, dose calculation and analy-
sis of large patient cohort, physics support for imaging guidance/delivery verification
techniques (e.g. prompt γ), advanced biological model development (e.g. based on
energy spectra, mechanistic, tumor micro-environment, etc.), multi-modality plan-
ning and delivery (i.e. PRECISE) and novel Monte Carlo codes and calculations.
Regarding the latter, several Monte Carlo codes were recently made available for
protons (Maneval et al. 2019, Jia et al. 2012a, Jia et al. 2012b, Senzacqua et al.
2017, Schiavi et al. 2017). Few works develop fast GPU-based computations for ions
heavier than protons (Qin et al. 2017, Qin et al. 2018), which would be particularly
valuable considering the introduction of novel particle modalities like raster-scanning
helium ion beams and multi-particle treatments. Other reports of an in-house de-
veloped TPS using a GPU-based ray-casting analytical engine report optimization
and computations under 10 seconds for intensity modulated proton therapy (IMPT)
(Matter et al. 2019).
For FRoG, concurrent efforts focus on the development of the various Lily Pads. Hy-
brid approaches (combining analytical and Monte Carlo methods) to dose computa-
tion promise compromise between accuracy and calculation speed (Barragán Mon-
tero et al. 2018), for example, by scoring heterogeneity index for each ray-trace.
If a certain threshold is exceeded, said PB will be flagged for post-processing, and
that PB will be pushed to separately calculated using GPU-based Monte Carlo
methods. Regarding GPU-based dose optimization, further FRoG developments
are currently underway in the PRECISE TPS for single and combined ion-beam
treatments. Moreover, as previously mentioned, although LETd has been demon-
strated as a poor indicator for RBE, one may choose to perform LETd-optimization
to reduce high-LET regions in distal OARs (Unkelbach et al. 2016, Unkelbach and
Paganetti 2018). Such techniques will be implemented in FRoG and thoroughly
investigated in the near future.
This is only a brief examination and sampling of the aims envisioned for FRoG.
The FRoG project extends partnership offers to other interested facilities. As the
role of light and heavy ion therapy in cancer therapy continues to expand, fast (e.g.
GPU-accelerated) and accurate systems like FRoG will serve as support tools for
both research and clinical investigations.
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Figure 3.8 – Potential study workflow for analysis of IPI clinical trials. To-date, HIT has
treated nearly 400 patients with either protons or carbon ion beams to combat
prostate-related disease. Since then, several treatment regimens were applied
differing in fractionation scheme and tissue radio-sensitivity factor (α/βx),
used in the local effect model (LEM) during biological dose optimization for
carbon ion treatments. With nearly a decade of clinical indication, what can
we learn about RBE and its impact on treatment outcome? The first HIT
prostate patient cohort from the prospective randomized phase 2 clinical trial
(Ion Prostate Irradiation, IPI) is collected here to study biological effect in
context of tumor control and normal tissue toxicity. The 92 IPI patients
received either proton therapy or carbon ion therapy with identical fraction
regime and prescription dose in the target, a total dose of 66 GyRBE admin-
istered in 20 fractions. Forward calculations including physical dose, LETd
and DRBE will be performed with FRoG. For improved prediction of actual
delivered dose, computation is performed using the original planning CT as
well as weekly control CTs to account for anatomical changes throughout
the treatment course. Biophysical uncertainty in prostate cancer treatment
planning and delivery will be investigated to assess clinical efficacy of the two
particle therapy modalities.
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Figure 3.9 – FRoG GUI version 2018.
4 Summary
Radiation therapy is a cornerstone in cancer treatment, with advances stemming
from interdisciplinary cooperation between physics, radiation biology and medicine
faculties. The emerging field of raster-scanning heavy ion particle therapy was se-
lected among the most promising interdisciplinary explorative fields with high rel-
evance for the “cancer moonshot program". Since the inception of the Heidelberg
Ion-beam Therapy (HIT) in 2009, over 5000 patients have been treated with light
and heavy ion beams (protons and carbon ions), exploiting its major advantages
over the conventional treatment using photons — providing a superior physical dose
distribution and increased relative biological effectiveness (RBE) in the tumor region
relative to the surrounding healthy tissues.
In this work, a multi-institutional collaboration between HIT (Heidelberg, Germany)
and the National Centre of Oncological Hadrontherapy (CNAO, Pavia, Italy), among
others, introduces a unique software, FRoG, for rapid and robust dose calculation
on a graphics processing unit (GPU) for four ions (p, 4He, 12C and 16O). As opposed
to a commercial treatment planning system (TPS) used in the clinic, FRoG is a
sandbox environment for radiation therapy research, capable of incorporating both
conventional and sophisticated models for physics and biology. Validating against
the gold-standard for accuracy (Monte Carlo simulation), we demonstrate the sys-
tem’s potential for upcoming integration in clinical studies.
To best interpret the overall clinical outcome in particle therapy, evaluation and
improvement of the predictive biophysical models, derived from in vitro studies,
in conjunction with physical beam delivery uncertainties remains paramount. This
is an important step to compare the strengths and weaknesses of currently estab-
lished biological models as well as reinforcing development of novel more heuristic
approaches. To this end, GPU-based software like FRoG represent a paradigm shift
for computation in biomedical research, making complex tasks like big-data analysis
commonplace. Deep learning algorithms could now be utilized in conjunction with
the 3D dose-distribution calculated by FRoG and imaging based spatially resolved
information (radiomics based endpoints) to identify data-driven biological effect ori-
ented dose definition. This is an important step towards the current US National
Cancer Institute and German Cancer Research Center (NCI-DKFZ) initiative to
define the impact of prescribed dose as a function of biophysical effects.
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When it comes to dose calculation accuracy in particle therapy, centers may be reluc-
tant to report common performance issues of the clinical treatment planning system
(TPS) in regions of high uncertainty. Present-day dose calculation in the clinic
may be knowingly compromised due to range uncertainty and/or limitations in lat-
eral beam modeling near the Bragg peak through beam paths with severe anatomic
heterogeneity. Unless clinics perform comprehensive validations in extreme clinical
conditions using a robust auxiliary dose calculation method, i.e. independent ana-
lytical or Monte Carlo engines, the achievable standards in treatment planning using
current practices remain unknown. In this work, we expose the computational limits
of various dose calculation systems, for both in-house developed and commercial,
used at HIT.
In addition to FRoG, a Monte Carlo-based treatment planning system (MCTP) was
developed at HIT for advanced dose calculation and optimization in delicate clin-
ical cases where the gold-standard for accuracy is crucial. Here, these two unique
systems are rigorously tested in a worst-case clinical scenario and compared to the
current clinical standards of a treatment planning system (TPS) in particle therapy
(SyngoPT®, Siemens, Erlangen, Germany). The SyngoPT® TPS was first imple-
mented at HIT in 2008 and is still in use today for light and heavy ion therapy
facilities worldwide.
Using multi-dimensional dosimetry, our results indicate that while the advanced
in-house systems excelled, clinically relevant discrepancies were observed between
measurement and predictions the clinical TPS, shedding light on the limitations of
commercial analytical algorithms in treatments with highly inhomogeneous patient
anatomy. We provide evidence that both Monte Carlo methods and innovative
dose engines (like FRoG) afford considerable improvements in prediction and should
become commonplace in particle therapy.
In conjunction with these two clinical particle therapy modalities at HIT, prepa-
rations to begin the first raster-scanning helium ion beam therapy program are
underway. Currently, helium ions are used solely for experimental studies at HIT,
and have remained unexploited worldwide since the shutdown of the clinical trials
at the Lawrence Berkeley Laboratory (LBL) in the early 1980’s. Their anticipated
clinical application will present numerous untapped medical and monetary advan-
tages, considering the superior biophysical properties to protons and the potential
for a compact facility design.
Prior to clinical application of helium ions, selection of an appropriate model for
relative biological effectiveness (RBE) is essential. In this work, we take the first
steps towards evaluating RBE for helium ion beams and three associated models
from a clinical standpoint. Inter- and intra-model dependencies were investigated
both in silico and subsequently benchmarked in vitro . Clinically relevant differences
in RBE prediction as a function of the various endpoints (dose, linear energy transfer
(LET) and tissue type) were observed. In addition, the models were incorporated
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into FRoG which will act as the primary computational tool during the clinical
routine as well as during the integration of the first commercial TPS for helium ion
therapy.
The cumulative thesis presented here encompasses the four following published
works:
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J, Abdollahi A and Mairani. Fast robust dose calculation on GPU for high-
precision 1H, 4He, 12C and 16O ion therapy: the FRoG platform. Sci. Rep.,
2018.
B. Choi K, Mein S„ Kopp B, Magro G, Molinelli S, Ciocca M and Mairani A.
FRoG—A New Calculation Engine for Clinical Investigations with Proton and
Carbon Ion Beams at CNAO. Cancers, 2018.
C. Mein S, Kopp B, Tessonnier T, Ackermann B, Ecker S, Bauer J, Choi K, Aricò
G, Ferrari A, Haberer T, Debus J, Abdollahi A and Mairani A. Dosimetric
validation of Monte Carlo and analytical dose engines with raster-scanning 1H,
4He, 12C and 16O ion-beams using an anthropomorphic phantom. Phys. Med.,
2019.
D. Mein S, Dokic I, Klein C, Tessonnier T, Böhlen T T, Magro G, Bauer J,
Ferrari A, Parodi K, Haberer T, Debus J, Abdollahi A and Mairani A 2019a
Biophysical modeling and experimental validation of relative biological effec-
tiveness (RBE) for 4He ion beam therapy. Radiat. Oncol., 2019.
Publication A details the methods, developmental process and validation of the
FRoG physical dose engine at HIT for clinical (p, 12C) and experimental beams
(4He and 16O). Publication B details dosimetric validations (for p and 12C) and clin-
ical investigations with FRoG as well as LETd and effective dose with variable RBE
models for carbon ions. Publication C investigates the limits of particle therapy
dose engines in an anthropomorphic phantom dosimetric study. Publication D in-
vestigates RBE prediction for helium ion beam therapy and establishes effective dose
computations with full Monte Carlo and GPU-accelerated analytical algorithms.
FRoG was recently introduced into the clinical and research pipeline at the National
Centre for Oncological Hadrontherapy (CNAO, Pavia, Italy) and is currently under
installation for clinical activity at the Danish Center for Particle Therapy (DCPT,
Aarhus, Denmark), and the Normandy Proton Therapy Center (Caen, France),
with other facility partnerships planned or pending. The extension of FRoG beyond
Heidelberg and further applications are explored.

5 Appendix
Dose calculation in heterogeneous settings requires physics knowledge of how parti-
cle beams interact in heterogeneous media and how complex anatomy or geometries
distort a pristine pencil beam (PB). Monte Carlo simulation inherently accounts
for this through particle-by-particle iteration. However, basic analytical algorithms
such as the pencil beam model will impose Bragg peak (BP) as a function of depth
and spread dose lateral based on an parameterized model, ignoring effects of lat-
eral heterogeneity on the incident beam. The depth wise alterations in density, as
long as the incident beam is along the central axis and the geometry is uniform
in the tangential plane, will be accounted for in the initial ray-tracing as a range
shift. However, lateral variations will distort the PB shape. Therefore, it is essen-
tial that analytical algorithms compensate for such effect of lateral heterogeneity
on PB pristiness. There are several approaches including ray-casting, WEPL-to
water-equivalent path length to point of interest (WEPL-to-POI), and pencil beam
splitting. Two main approaches have been implemented in FRoG, both using a pen-
cil beam splitting approach, and will be summarized in the following sections. The
goal of pencil beam decomposition is to reconstruct the original distribution with a
particular spatial arrangement of scaled sub-Gaussian (normal) distribution, which
becomes a unique PB during ray-tracing and computation of lateral dose evolution.
This technique becomes of particular use when heterogeneities are introduced into
the geometry as demonstrate by Figure 5.1, with PB imaging on a split medium
geometry.
All solutions must begin by recalling the definition of a Gaussian function (G(x)),
a common continuous probability distribution used in many facets of science:
Gµ,σ(x) =
1
σ
N
(
x− µ
σ
)
(5.1)
where µ, σ and N presented the off-set, standard deviation of the Gaussian and
normalization factor N, respectively.
1) Dynamic splitting of Gaussian pencil beams
Methods of lateral heterogeneity handling date back to the 1990’s , where Schaffner
et al. present a fluence-dose model (FDM) approach where each scanned pencil
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Figure 5.1 – Effect of inhomogeneous geometry (simple two slab system) on PB shape.
The "ground truth" Monte Carlo prediction (top) is presented above three
analytical approaches: (from left to right) original PB model, ray-casting and
fluence-dose model (Schaffner et al. 1999).
Figure 5.2 – As presented in Kanematsu et al., Lateral profiles of the fixed approximations
for the dynamic splitting method. The original normal distribution (high-
lighted gray region) and approximate solutions (discrete) for reconstruction
of order (a) N=2, (b) N=3 and (c) N=4 (solid lines) composed of a subset of
sub-Gaussian distributions (dashed lines).
beam is decomposed into elemental PBs, sometimes referred to as daughter PBs
and were specifically examined the emerging proton therapy field at the time.
More recent works investigate viable approaches for heavy ions, as detailed in Kane-
matsu et al. where the authors provide fixed approximate solutions for three unique
denominations. in a 2D coordinate system, the original Gaussian distribution can
be decomposed with multiplicity M=2, M=3, and M=4, as follows (Fig. 5.2):
N2(x) =
1
2
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2
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2
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2
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]
(5.2)
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The works presented in Kanematsu et al. expands on the mathematical formalism
and suggested approach to implementation. The authors makes use of “the self-
similar nature of Gaussian distributions” for applications in heavy ion therapy dose
calculation (specifically carbon ion beams) which enables the dynamic splitting of
Gaussian beams to mimic effects of lateral heterogeneity on PB morphing. From a
computational speed standpoint, the dynamic splitting method makes possible fast
run-times while moderately accounting for lateral heterogeneity effects. The success
of such a techniques is highly dependent on the extent of heterogeneity and quality
of the beam-line to transport of particle beam with lateral spread characteristics
similar to a single Gaussian. Considering the complexity of the HIT beam-line,
FRoG results, which implemented the dynamic splitting approach were sufficient in
patients with moderate heterogeneity for heavy ions (12C and 16O). For the lighter
ions and cases with severe heterogeneity, the dynamic splitting method was below
satisfactory when compared to Monte Carlo predictions. Therefore, the following
section explores higher order approximations to Gaussian decomposition.
2) Beamlet superposition approach of Gaussian pencil beams
More recently, works present a novel analytical algorithm for the calculation of
scanned ion beams called the the beamlet superposition approach. Again, beginning
with the mathematical expression for a Gaussian distribution:
G (r;µr, σr) =
1
σr
√
2pi
exp
(
−(r − µr)
2
2σ2r
)
(5.5)
which a mean of µr and standard deviation σr. As stated in Russo et al., G (r;µr, σr)
can be approximated with a weighted superposition of N sub-Gaussian distributions
g(r; 0, σ˜r). For the case where G (r;µr, σr) is composed of an infinite number of
sub-Gaussian components within the bounds of ±∞, a convolution can be written
as:
G (r;µr, σr) = g (r;µr, σˆr) ∗ g (r; 0, σ˜r) (5.6)
where g (r;µr, σˆr) represents a weight function with a standard deviation hatσr =√
σ2r − σ˜2r .
For practical purposes in dose calculation in a patient (non-infinite geometry), the
Gaussian weight function g(r;µr, σˆr) can be approximated a set equally spaced
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Dirac’s delta (increments of δr) between 3.5σˆr and +3.5σˆr. Democratisation of
equation 5.6 yields
g (r;µr, σr) '
+N−1
2∑
i=−N−1
2
gr,ig (r;µr + i∆r, σ˜r) (5.7)
Determination of unique weights gr,i for each sub-Gaussian is visually demonstrated
in Figure 5.3 by integration of the original Gaussian between the iterative bounds
of each centralized Dirac delta, giving the expression
gr,i =
∫ µr+(i+ 12)∆r
µr+(i− 12)∆r
g (r;µr, σˆr) dr. (5.8)
Figure 5.3 – Following the work of Russo et al., 2D representation of beamlet superposi-
tion method is presented for an N=21 PB subdivision. The original normal
distribution (solid black) and approximate solution (dashed blue) via super-
position of an N=21 sub-Gaussian distributions (gray lines).
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In FRoG, the beamlet superposition method described above is implemented for
raster-scanning proton, helium carbon and oxygen ion beams.
3) Lateral heterogeneity handling in FRoG
FRoG is an analytical dose engine with a Monte Carlo-derived database (both phys-
ical and biophysical parameters) and uses a novel approach to the analytical ap-
proach, called the dual pencil beam (DPB) model. For lateral heterogeneity han-
dling, high-order pencil-beam subdivision with the beamlet superposition approach
described in Russo et al. is applied with a splitting multiplicity of 700 (for p and
4He) and 350 (for 12C and 16O). The source and lateral dose evolution charac-
teristics are described using high-order triple Gaussian (TG) model. Compared to
existing commercial systems with analytical dose engines, RayStation, for example,
handles anatomic heterogeneity by a hard-coded spatially distributed pencil beam
subdivision of 19 (RaySearch). FRoG is the first GPU-based dose engine for (4He,
12C and 16O).
The DPB is established during Monte Carlo simulation of the HIT beam-line for
depth dose and lateral dose evolution of the 255 available energies by separately
scoring dose contributions from the primary beam particles which interact within the
Tungsten wiring of multi-wire proportional chamber (MWPC). This is particularly
important for lower Z ions due to relatively significant impact on the pristine beam
by inducing large angle scattering, and in turn, an increased low-dose envelope of the
impinging particle beam. The effects were not explicitly considered for the higher Z
particle beams (12C and 16O).
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Figure 5.4 – Dual PB (DPB) is implemented in FRoG for p and 4He separately considering
primary particles interacting within the Tungsten wiring of MWPC versus the
pristine beam (left). Beamlet and beamlet superposition Gaussian for the
primary PB (DPB-1, bottom) and the secondary (DPB-2, top) are displayed
(right). The superposition (aggregate) of DPB-1 and DPB-2 yield the original
primary beam fluence pattern.
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